University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2016

Proteostasis Responses to Endogenous Alpha-Synuclein
Aggregation in the Brain
Scott Edward Ugras
University of Pennsylvania, scugras@sas.upenn.edu

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Biochemistry Commons

Recommended Citation
Ugras, Scott Edward, "Proteostasis Responses to Endogenous Alpha-Synuclein Aggregation in the Brain"
(2016). Publicly Accessible Penn Dissertations. 2068.
https://repository.upenn.edu/edissertations/2068

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2068
For more information, please contact repository@pobox.upenn.edu.

Proteostasis Responses to Endogenous Alpha-Synuclein Aggregation in the Brain
Abstract
α-Synuclein aggregation is implicated in several neurodegenerative diseases, including Parkinson’s
disease (PD) and dementia with Lewy Bodies (DLB). Changes in cellular signaling pathways induced by
this aggregation may contribute to cell death and disease pathogenesis. To investigate this, we used
quantitative proteomics to measure the relative abundance changes of the proteome and
phosphoproteome in response to aggregation of endogenous α-synuclein in the brain of a mouse model.
Aggregation in this model is induced by the intrastriatal injection of α-synuclein pre-formed fibrils and
recapitulates several cardinal features of human PD, including progressive aggregation concomitant with
dopaminergic degeneration and motor symptoms. We quantified the relative abundance changes of 5,290
proteins and 2,763 phosphosites in wildtype mice and found significant changes in vesicle-mediated
transport, RNA processing and the immune response. The immunoproteasome, an altered form of the
constitutive proteasome that is induced in response to stress, was elevated in response to α-synuclein
aggregation. Increased levels and activity of the immunoproteasome were found in human DLB compared
with age-matched healthy controls. Additionally, the immunoproteasome degrades α-synuclein fibrils
more efficiently than the constitutive proteasome. This is the first documented role of the
immunoproteasome in synucleinopathies.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Biochemistry & Molecular Biophysics

First Advisor
Harry Ischiropoulos

Keywords
Parkinson's, Proteomics, Proteostasis, Synuclein

Subject Categories
Biochemistry

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/2068

PROTEOSTASIS RESPONSES TO ENDOGENOUS ALPHA-SYNUCLEIN AGGREGATION IN
THE BRAIN
Scott Edward Ugras
A DISSERTATION
in
Biochemistry and Molecular Biophysics
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2016

Supervisor of Dissertation
__________________________________________________________
Harry Ischiropoulos, Ph.D.
Research Professor, Department of Pediatrics, Children's Hospital of Philadelphia; Department of
Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University
of Pennsylvania

Graduate Group Chairperson
__________________________________________________________
Kim A. Sharp, Ph.D.
Professor, Department of Biochemistry and Biophysics
Dissertation Committee
Yair Argon, Ph.D. Professor, Department of Pathology and Laboratory Medicine (Chair)
Walter Englander, Ph.D. Professor, Department of Biochemistry and Biophysics
Rahul Kohli, M.D., Ph.D. Assistant Professor, Department of Medicine
E. James Petersson, Ph.D. Associate Professor, Department of Chemistry

1

PROTEOSTASIS RESPONSES TO ENDOGENOUSE ALPHA-SYNUCLEIN AGGREGATION IN THE BRAIN
COPYRIGHT
2016
Scott Edward Ugras

ii

Eppur si muove
- Galileo Galilei

iii

ACKNOWLEDGMENTS
First and foremost, I would like to thank Harry Ischiropoulos for his guidance over the
past several years. Harry has consistently pushed me to be the best thinker and problem
solver I can be, and has truly become a mentor to me. I look forward to continuing to
receive mentorship and guidance from him in the years to come.
I would like to thank the members of my thesis committee, including Yair Argon, Rahul
Kohli, Walter Englander, and James Petersson, who have helped me both inside and
outside of my committee meetings.
I would like to thank members of the Ischiropoulos lab who have been scientific peers
and have helped make doing research in lab fun, especially members of the ‘Synuclein
Data Club’ including Danielle Mor, Malcolm Daniels and Dick Lightfoot.
I would like to thank my friends in the BMB program who have helped make my graduate
school experience enjoyable, including Chris Yarosh, Michael Soo, Bengi Turegun, Dan
Ricketts and Eric Babiash.
I am especially grateful for the support my family has provided me throughout my life,
and particularly throughout graduate school. The older I get the more I appreciate all the
love, support and guidance I have received from all members of my family, especially my
parents, and my siblings Sandra, Steven and Stacy.
Finally I would like to thank my girlfriend Hilary. Having you in my life has taught me so
much about finding balance, being confident and pursuing my passions, things I could
not have learned in the classroom or at the bench. Thank for you challenging me to
become a better person.

iv

ABSTRACT
PROTEOSTASIS RESPONSES TO ENDOGENOUS ALPHA-SYNUCLEIN
AGGREGATION IN THE BRAIN
Scott Edward Ugras
Harry Ischiropoulos

α-Synuclein aggregation is implicated in several neurodegenerative diseases, including
Parkinson’s disease (PD) and dementia with Lewy Bodies (DLB). Changes in cellular signaling
pathways induced by this aggregation may contribute to cell death and disease pathogenesis. To
investigate this, we used quantitative proteomics to measure the relative abundance changes of
the proteome and phosphoproteome in response to aggregation of endogenous α-synuclein in
the brain of a mouse model. Aggregation in this model is induced by the intrastriatal injection of
α-synuclein pre-formed fibrils and recapitulates several cardinal features of human PD, including
progressive aggregation concomitant with dopaminergic degeneration and motor symptoms.
We quantified the relative abundance changes of 5,290 proteins and 2,763 phosphosites in
wildtype mice and found significant changes in vesicle-mediated transport, RNA processing and
the immune response. The immunoproteasome, an altered form of the constitutive proteasome
that is induced in response to stress, was elevated in response to α-synuclein aggregation.
Increased levels and activity of the immunoproteasome were found in human DLB compared
with age-matched healthy controls. Additionally, the immunoproteasome degrades α-synuclein
fibrils more efficiently than the constitutive proteasome. This is the first documented role of the
immunoproteasome in synucleinopathies.
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CHAPTER 1
Introduction
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1.1 Proteostasis
Proteins have an intrinsic ability to adopt three-dimensional conformations that are necessary
to execute proper functions1,2. Proteins may fail to adopt or maintain their proper conformation,
however, due to errors in protein folding, mutations, or changes in binding partners, pH or
concentrations3. To combat these potentially toxic events, cells have evolved diverse and
integrated cellular machinery that maintains proper protein homeostasis through various
cellular pathways. These proteostasis networks regulate protein expression, degradation,
binding partners, locations and conformations4. A key element of proteostasis is its ability to
dynamically regulate the proteome, through transcriptional and post-translational
modifications4,5.
Perturbations in the proteostasis networks, whether through age-related decline, environmental
factors, or mutations, can contribute to diseases including neurodegenerative diseases6, aging7–
9

, cystic fibrosis10, cancer11,12 and Diabetes13. Intriguingly, attempts to modulate central nodes

within proteostasis networks, such as the molecular chaperone Hsp90, have shown some
therapeutic promise14. As our knowledge of proteostasis continues to advance, several other
targets will emerge that have therapeutic potential12.
The three major elements of the proteostasis network include chaperones that assist in proper
protein folding15,16, chaperone-mediated autophagy that clears misfolded proteins by
translocating them into the lysosomal lumen, and the ubiquitin-proteasome system that targets
specific proteins for degradation.

1.1.1 Chaperones

2

Despite the intrinsic ability of proteins to spontaneously adopt their native three-dimensional
conformations, molecular chaperones often assist protein folding17. The complexity of protein
folding in vivo, especially due to the crowded molecular environment within cells, increases the
likelihood of aberrant protein aggregation18. Furthermore, large, multidomain proteins have a
greater propensity to fold into off-pathway, misfolded intermediates19.
Molecular chaperones assist in protein folding without being part of the final protein structure16.
The Heat Shock Proteins (HSPs) are upregulated in times of stress or increased protein
aggregation20. Several classes of HSPs exist and have different functions. The Hsp70 family is a
group of constitutively expressed, highly conserved, ATP-dependent chaperones that assist
folding of nascent proteins emerging from the ribosome and refold misfolded protein
aggregates21,22. The Hsp90 chaperones are ATP-dependent and assist in proper protein folding
events downstream of Hsp70s and are critical in many signaling events23–26. Another class of
chaperones, chaperonins, are ATP-dependent molecular machines that include the well-studied
GroEL/ES system27,28.

1.1.2 Chaperone-Mediated Autophagy

Chaperone-mediated autophagy (CMA) is a degradation pathway that targets cytosolic proteins
for lysosomal destruction29. CMA upregulation occurs in response to oxidative stress30 and
exposure to toxic compounds31. CMA substrates typically contain the pentapeptide KFERQ that
is recognized by the Hsp70 member hsc70 when the motif is surface exposed. Hsc70 is part of
the larger complex known as the CMA cargo recognition complex32. The newly formed
substrate-CMA cargo recognition complex is then targeted to the lysosomal membrane for
3

translocation. Lysosome-associated membrane protein type 2A (LAMP-2A) is a single-span
membrane protein that participates in substrate binding and translocation into the lumen of the
lysosome29,33. The highly acidic intraluminal environment and lysosomal proteases then rapidly
degrade substrate proteins.
CMA has been implicated in human pathology, including aging34 and neurodegenerative
diseases35. Age-related disruptions in lysosomal membrane dynamics cause a decline in total
LAMP-2A levels that contribute to the decreased rate of CMA with age36,37. In Parkinson’s
disease (PD), where mutations and aggregation of α-synuclein are implicated in disease
pathology, wildtype α-synuclein but not PD-linked mutant forms can be degraded by CMA38,39.
Wildtype forms of leucine-rich repeat kinase 2 (LRKK2), another protein that is mutated in some
cases of familial PD, are efficiently degraded by CMA but PD-linked mutant forms are not40. In
Alzheimer’s disease, the protein tau aggregates in the brain and forms intracellular tangles41.
Normally, wildtype tau undergoes degradation by CMA but mutant tau undergoes differential
degradation that may contribute to AD42. These findings suggest that the CMA arm of the
proteostasis network plays a key role in maintaining functional protein networks.

1.1.3 Ubiquitin-Proteasome System

1.1.3.1 Substrate Targeting

The ubiquitin proteasome system (UPS) is the major cellular system that degrades misfolded
proteins43–45. Proteins are targeted for degradation through a serious of sequential steps
beginning with the covalent attachment of the 76-amino acid, highly conserved ubiquitin (Ub)
4

protein. First, the E1 Ub-activating enzyme covalently binds to Ub in an ATP-dependent process.
Then, this Ub is transferred to a cysteine residue on the E2 Ub-conjugating enzyme. Then this
activated E2 collaborates with the E3 enzyme to transfer the Ub to the target substrate. This
mono-Ub substrate can then undergo further ubiquitination resulting in a polyubiquitinated
protein. Substrates with at least four Ub are then recognized by the mature proteasome for
degradation.

1.1.3.2 Constitutive Proteasome

The proteasome is composed of a 20S core catalytic subunit and two 19S regulatory caps that
are responsible for substrate recognition46–48. The 20S core is composed of four seven-subunit
rings, including two outer rings composed of seven α subunits and two inner rings composed of
seven β subunits. These subunits are arranged in a α1-7β1-7β1-7α1-7 configuration. The β1, β2 and β5
subunits confer the catalytic activity and specificity of the proteasome. The 19S caps regulate
several steps in proteasomal degradation of substrate targets in an ATP-dependent manner,
including entry into the 20S core, disassembly of the polyubiquitin chains, and binding to
substrate46.

1.1.3.3 Immunoproteasome

The immunoproteasome is an alternative form of the constitutive proteasome that is expressed
under conditions of proinflammatory stimuli or oxidative stress49–51. In the 20S core of the
immunoproteasome, the three catalytic subunits, β1, β2 and β5, are replaced with Lmp2, MECL-1
5

and Lmp7 (also known as β1i, β2i and β5i), respectively52 (Figure 1.1). β2 and MECL-1 each exhibit
trypsin-like activity and β5 and Lmp7 each exhibit chymotrypsin-like activity. Lmp2 and β1 differ,
however, in that Lmp2 exhibits chymotrypsin-like activity whereas β1 exhibits caspase-like
activity53. Assembly of the immunoproteasome by incorporation of the catalytic subunits occurs
in response to interferon gamma (IFNγ) and is 4-fold faster than assembly of the constitutive
proteasome54. Additionally, the immunoproteasome has a greater degradation efficiency of
basic proteins compared with the constitutive proteasome55. These differences result in distinct
kinetics and cleavage site preference of the immunoproteasome, resulting in the generation of
antigenic peptides that are presented to major histocompatibility (MHC) class I molecules56,57.

Figure 1.1 Subunit composition of the constitutive proteasome and the immunoproteasome.
Representation of the subunits present in the constitutive proteasome and the immunoproteasome.
Upon stimulation with cytokines such as IFNγ, the catalytic subunits of the immunoproteasome, Lmp2,
MECL-1 and Lmp7 (also known as β1i, β2i and β5i), replace the catalytic subunits of the constitutive
58
proteasome, namely β1, β2 and β5. Figure adopted from McCarthy and Weinberg .
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The immunoproteasome has been implicated in a number of human diseases59, including
autoimmune diseases60 and neurodegenerative diseases. Mutations in the PSMB8 gene that
encodes Lmp7 have been found to cause chronic atypical neutrophilic dermatosis with
lipodystrophy and elevated temperature (CANDLE)61 and joint contractures, muscle atrophy,
microcytic anemia, and panniculitis-induced childhood-onset lipodystrophy (JMP)62.
Immunoproteasome levels and activity were found to be elevated in the brains of patients who
had Huntington’s disease63. Lmp2-positive staining was also found predominantly within
neurons and overlapped with 5% of cortical aggregates. Levels of the immunoproteasome have
been found to be increased in the Alzheimer’s disease (AD) brain compared with age-matched
healthy brain64. Subsequent studies found that this increase is predominantly found in reactive
glia that surrounds amyloid-β plaques in the AD brain65.

1.2 Protein Misfolding in Neurodegeneration

1.2.1 Spreading of Protein Aggregates

Neurodegenerative diseases include a broad-array of progressive diseases afflicting the central
nervous system (CNS)66. They are a major burden on older people and are predicted to increase
in prevalence as populations continue to age67. Though these diseases affect different neuronal
populations and manifest with different symptoms, they share a common feature of the
accumulation of insoluble protein aggregates. These culpable proteins include amyloid-β and
tau in AD, TDP43 and FUS in Amyotrophic Lateral Sclerosis (ALS), and α-synuclein in PD. These
aggregates come in two major forms, either amyloid fibrils or amorphous aggregates.
7

While amorphous aggregates do not contain any regular structural characteristics, amyloid
fibrils are highly ordered polymers that are rich in β-sheets68. Proteins have an intrinsic ability to
adopt the amyloid conformation, though the proteostasis network prevents most from doing
so69. These fibrils contain filaments of parallel β-strands that run perpendicular to the fibrillar
axis, forming a cross-β structure70. The hydrogen bonds that form between the backbones of
these strands provide the stability that is a characteristic of amyloid fibrils. This stability makes
amyloid fibrils particularly recalcitrant to proteostasis pathways that degrade misfolded
proteins. Amyloid fibrils are generated through a self-templating process composed of a
nucleation phase followed by a growth phase71. In this process, oligomers of amyloid fibrils form
first, and then recruit soluble forms of the same protein to grow at their ends. Once a critical
nucleus is formed, growth rapidly proceeds until all available protein is consumed, resulting in a
thermodynamically stable amyloid fibril.
This self-templating process, also known as seeding, is thought to underlie the predictable
pathological spread of protein aggregates seen in neurodegenerative diseases, including AD, ALS
and PD67. Strong evidence for seeding in neurodegenerative diseases comes from studies in PD
patients who received fetal nigral transplants. In one study, human fetal neurons that were
transplanted into a 61-year old patient contained Lewy Body-like aggregates characteristic of
the PD brain only fourteen years after transplantation72. In another study, two patients who
received fetal mesencephalic dopaminergic neurons developed α-synuclein positive, Lewy Bodylike aggregates in the grafted neurons73. These studies provide evidence that in humans, protein
aggregates can spread from host to graft, supporting the theory of cell-to-cell transmission in
protein aggregation disorders. Additionally, studies in model organisms also support this theory,
especially a recently developed mouse model of progressive α-synuclein aggregation74. In this
8

model, preformed fibrils of α-synuclein are intrastriatally injected into the right striatum of a
non-transgenic mouse, resulting in progressive aggregation of endogenous α-synuclein
concomitant with dopaminergic degeneration and motor phenotype. Critically, injection into αsynuclein-null mice does not result in degeneration or motor phenotype, providing evidence for
the progressive aggregation of endogenous α-synuclein as being critical for pathology. This
model of progressive aggregation of endogenous α-synuclein driven by a seeding mechanism
has been reproduced in both mice75,76 and rats77.

1.2.2 Neurodegenerative Disease

1.2.2.1 Alzheimer’s Disease

AD is the most common neurodegenerative disease worldwide, affecting over 45 million people
in 2015 and is expected to grow to 115 million people by 205078. An estimated 9.9 million new
cases of AD occur each year, and the risk of developing AD increases exponentially with age78.
Accumulation of extracellular aggregates of amyloid-β and cytoplasmic aggregates of tau are the
pathological hallmarks of AD79. There is strong evidence for the progressive spreading of
aggregates in the AD brain.
The major form of aggregated amyloid-β in the AD brain is a 42 amino acid peptide formed from
the cleavage of amyloid precursor protein (APP)80,81. Recombinant forms of this peptide form
amyloid fibrils, and these fibrils are capable of accelerating the aggregation of soluble forms of
the same protein82. Injection of brain extracts from AD patients into APP transgenic mice
induces progressive spread of pathology in the brain83. Additionally, inoculation with synthetic
9

amyloid-β aggregates induced aggregation in the APP transgenic mouse brain84. The aggregation
of tau, a protein that binds to and stabilizes microtubules, is linked to AD and other
tauopathies85,86. Injection of lysate from human brain that suffered from tauopathy into
transgenic mouse that expressed human tau resulted in the development of tau-positive
aggregates87. Collectively, these data support the notion that spreading of aggregates in the
brain contributes to the pathogenesis of AD.

1.2.2.2 Amyotrophic Lateral Sclerosis

ALS (also known as Lou Gehrig’s Disease) is a progressive motor degenerative disorder with a
prevalence of 4-6 per 100,000 that is uniformly fatal within 1-5 years of disease onset88.
Mutations in the RNA-binding proteins89 TDP4390–94 and FUS95,96 cause familial forms of ALS.
Cytoplasmic inclusions containing these proteins have been found in ALS patients, indicating
that aggregation may contribute to disease97. Recombinant TDP43 forms non-amyloid
aggregates in vitro under standard aggregating conditions98. The ALS-linked mutations Q331K
and M337V accelerate this aggregation in cell-free systems and are toxic when expressed in
cells98. Similarly, FUS also rapidly misfolds into non-amyloid, amorphous aggregates, and is toxic
when expressed in cells99. Postmortem analysis of ALS patients reveals that tissues directly
connected to the cortex develop TDP43 inclusions once the cortex does, but those tissues not
connected do not100. These findings support a role for protein aggregation and spreading in the
pathology of ALS.
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1.3 Parkinson’s disease

1.3.1 Disease Overview

PD is a neurodegenerative disorder of the CNS that afflicts over 50 million people worldwide101.
First described in an 1817 essay by the English surgeon James Parkinson102, it is currently the
second most common neurodegenerative disease worldwide103. Degeneration of dopamine
producing neurons in the substantia nigra pars compacta is a defining feature of PD104. This
degeneration contributes to both motor and non-motor symptoms that PD patients exhibit. The
five major motor symptoms of PD include bradykinesia, resting tremor, muscle rigidity, postural
change and gait. Non-motor symptoms include cognitive changes, sleep and sensory
deprivations, and constipation. PD patients may also experience dementia, particularly at later
stages of the disease105. Estimates of the prevalence of dementia with patients who are
diagnosed with PD vary, but most studies estimate 30%-40%106,107. Similar to other
neurodegenerative diseases, age is the greatest risk factor for developing PD. Approximately
10% of PD cases are familial versus 90% that are sporadic108.

1.3.2 Pathology of Parkinson’s disease

The histopathological hallmark of PD is dense, cytoplasmic inclusions known as Lewy Bodies
(LBs)104. The presence of LBs in different brain regions defines the progression of PD, starting
from the olfactory bulb in stage 1 and progressing to the neocortex in stage 6109. Though some
exceptions to this progression have been found110,111, most cases follow this staging
scheme112,113. LBs contain hyperphosphorylated α-synuclein fibrils114 (more on α-synuclein in
11

Chapter 2). The aggregation of α-synuclein and formation of LBs is thought to contribute to the
degeneration of dopamine-producing neurons in PD115. Additionally, α-synuclein mutations that
cause PD have been identified116–120, along with gene multiplications121–123. These data strongly
implicate a role for α-synuclein aggregation in the pathogenesis of PD.

1.3.3 Treatments

PD is currently incurable and no disease modifying therapies exist. Most current therapies aim
at elevating dopamine levels or potentiating dopamine pathways. The first therapy shown to be
effective at mitigating PD symptoms was levodopa in 1967124. Levodopa, a precursor to
dopamine that is able to cross the blood-brain barrier, is part of the current therapeutic regime.
It is typically administered along with carbidopa, a dopa decarboxylase inhibitor, and is often the
first line treatment for patients over 55 years of age. This regime is usually effective for 5 years
at delaying motor symptoms of PD125. For patients under 55 years of age, a dopamine agonist,
such as ropinirole or rotigotine, is typically the first line treatment. Selective type B monoamine
oxidase inhibitors can also be administered and function by decreasing the conversion of
dopamine to 3,4-Dihydroxyphenylacetic acid (DOPAC). At more advanced stages of PD, deep
brain stimulation of the subthalamic nucleus is more effective at managing symptoms in the
majority of patients compared with medical treatment alone, though the risk of adverse effects
is greater126.
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2.1 Abstract
α-Synuclein is a conserved, abundantly expressed protein that is partially localized in presynaptic terminals in the central nervous system.

The precise biological function(s) and

structure of α-synuclein are under investigation. Recently, the native conformation and the
presence of naturally occurring multimeric assemblies have come under debate. These are
important deliberations because α-synuclein assembles into highly organized amyloid-like fibrils
and non-amyloid amorphous aggregates that constitute the neuronal inclusions in Parkinson’s
disease and related disorders.

Therefore understanding the nature of the native and

pathological conformations is pivotal from the standpoint of therapeutic interventions that
could maintain α-synuclein in its physiological state. In this review, we will discuss the existing
evidence that define the physiological states of α-synuclein and highlight how the inherent
structural flexibility of this protein may be important in health and disease.
2.2 Introduction
α-Synuclein is a soluble protein that is highly conserved in vertebrates and abundantly
expressed in nervous tissue (Jakes et al., 1994). It was first discovered in 1988 in association
with purified synaptic vesicles from the Torpedo electric ray (Maroteaux et al., 1988). Soon
afterward α-synuclein was found to be widely distributed across the mammalian brain and
localized to presynaptic nerve terminals, suggesting functions related to neurotransmission (Iwai
et al., 1995). Independent of these reports, α-synuclein was identified as the precursor to a
hydrophobic peptide found in Alzheimer’s disease senile plaques, termed the non-Aβ
component of Alzheimer’s disease amyloid (NAC) (Uéda et al., 1993). The α-synuclein gene was
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also dynamically regulated during song learning in zebra finch, supporting a role in synaptic
plasticity (George et al., 1995).
The discovery of a mutation in the α-synuclein gene that was associated with autosomal
dominant inheritance of Parkinson’s disease (PD) provided the impetus for a major shift in αsynuclein research (Polymeropoulos et al., 1997). PD is a neurodegenerative disorder primarily
characterized by the loss of dopamine-producing neurons in the substantia nigra pars compacta
resulting in motor impairment. Since the original publication of the A53T mutation, several
mutations, as well as multiplications of the α-synuclein gene have been linked to PD (ChartierHarlin et al., 2004; Krüger et al., 1998; Lesage et al., 2013; Pasanen et al., 2014; Proukakis et al.,
2013; Singleton et al., 2003; Zarranz et al., 2004; Ferese et al. 2015) Furthermore, several
antibodies against α-synuclein robustly detect the well-known pathoanatomical features of PD,
Lewy bodies and Lewy neurites, in postmortem brain tissue from patients with sporadic PD as
well as other related neurodegenerative disorders (Baba et al., 1998; Spillantini et al., 1997;
Takeda et al., 1998). The finding that wildtype α-synuclein was detected in Lewy bodies and
Lewy neurites prompted the publication of numerous studies that investigated the biochemistry
and biology of α-synuclein. Despite the rather impressive body of work several fundamental
questions remain: What is the physiological function of α-synuclein? What is the structure of
native α-synuclein?

What factors contribute to the induction of aggregation-competent

conformational states of α-synuclein? In this review, we will briefly review the evidence for the
different biological functions and discuss ongoing efforts to precisely define physiological
structures of α-synuclein.
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2.3 The physiological function(s) of α-synuclein
The initial studies indicated that α-synuclein is not required for neuronal development or
synapse formation, but instead may modulate synaptic activity. In rodents, α-synuclein is
detected close to the time of birth and continues to increase until one month of age, when it
reaches a steady-state level that is maintained throughout adulthood (Shibayama-Imazu et al.,
1993). Similarly, in cultured rat neurons the development of synapses precedes α-synuclein
expression and translocation to axonal terminals (Murphy et al., 2000; Withers et al., 1997). The
hypothesis that α-synuclein regulates synaptic activity was directly tested in mice lacking αsynuclein. α-Synuclein null mice develop normal brain architecture and synaptic contacts, and
do not exhibit gross behavioral phenotypes (Abeliovich et al., 2000).

However, subtle

abnormalities in activity-dependent neurotransmitter release have been observed.

Upon

repeated stimulation, dopaminergic synapses from α-synuclein null mice sustain highly elevated
dopamine release (Abeliovich et al., 2000; Yavich et al., 2004). Functional redundancy among αsynuclein and the other synuclein family members, β- and γ-synuclein, may account for the mild
phenotypes observed in the single knockout. In α/β-synuclein double knockout mice, synaptic
plasticity appears unaltered relative to α-synuclein single knockouts, although dopamine levels
in the striatum are reduced (Chandra et al., 2004). The importance of synucleins is particularly
highlighted by α/β/γ-synuclein triple knockouts, which have decreased life span and late-onset
synaptic dysfunction compared with wildtype mice (Burré et al., 2010; Greten-Harrison et al.,
2010). Triple knockouts in another study had motor deficits and decreased striatal dopamine,
along with abnormal dopamine neurotransmission (Anwar et al., 2011). Collectively, these
reports emphasize the important role of the synucleins in long-term synaptic maintenance and
plasticity.
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Synaptic vesicle trafficking. Examination of the role of α-synuclein in the synaptic vesicle cycle
has yielded conflicting results. Depletion of α-synuclein from rodent hippocampal neurons both
in vivo and in vitro induces a significant loss of undocked synaptic vesicles, suggesting that αsynuclein acts to replenish or maintain the resting and/or reserve vesicle pools (Cabin et al.,
2002; Murphy et al., 2000). In contrast, another study found that increasing α-synuclein in
rodent hippocampal neurons reduces the recycling pool of vesicles (Nemani et al., 2010). The
effect of α-synuclein on vesicles docked at the plasma membrane prior to exocytosis is similarly
unclear. Knockout or knockdown of α-synuclein in rodent hippocampal neurons results in either
a decrease or no change in the number of docked vesicles (Cabin et al., 2002; Murphy et al.,
2000). Conversely α-synuclein expression in PC12 cells causes an accumulation of vesicles at the
plasma membrane and impairment of exocytosis (Larsen et al., 2006).

However, in mice

modestly overexpressing α-synuclein (levels are not associated with neurotoxicity), hippocampal
synapses display a redistribution of vesicles away from the active zone. The density of vesicles
in synaptic boutons is also reduced, consistent with α-synuclein-mediated inhibition of vesicle
clustering. This is supported by α-synuclein-induced defects in vesicle re-clustering following
endocytosis in rat hippocampal neurons (Nemani et al., 2010). Still, opposing results have been
obtained from yeast, in which α-synuclein expression results in massive accumulations of
vesicles that co-localize with Rab GTPases (Gitler et al., 2008; Soper et al., 2008). Likewise, αsynuclein has been shown to restrict vesicle diffusion away from synapses in mouse
hippocampal neurons (Wang et al., 2014). Several lines of evidence, therefore, support the
participation of α-synuclein in synaptic vesicle trafficking, though the specific steps for which it
may be most important, i.e. vesicle docking, recycling and/or re-clustering, remain unclear.
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Chaperone-like activity and neurotransmitter release.

α-Synuclein and the other synuclein

family members may act as molecular chaperones, facilitating neurotransmitter release.
Cysteine-string protein α (CSPα) is a chaperone that is essential for synaptic health; its deletion
in mice leads to a decrease in SNARE protein complexes, nerve terminal degeneration, motor
impairment and death. When expressed in CSPα-deficient mice, α-synuclein is able to rescue
this degenerative phenotype and restore levels of SNARE complexes in synaptic terminals.
Moreover, mice lacking both α-synuclein and CSPα exhibit an exacerbated phenotypic decline
(Chandra et al., 2005). These findings suggest that α-synuclein is able to complement the
activity of CSPα in promoting synapse integrity. Direct evidence for the interaction of αsynuclein with SNARE complexes was documented by co-immunoprecipitation of α-synuclein
with SNARE proteins and specific binding to the vesicle-associated SNARE protein
synaptobrevin-2.

In mammalian cells and purified in vitro systems, α-synuclein dose-

dependently facilitates SNARE complex assembly (Burré et al., 2010). Additional support for
chaperone-like activity includes sequence homology between α-synuclein and 14-3-3 protein
chaperones as well as the association of α-synuclein with 14-3-3 and its binding partners in rat
brain (Ostrerova et al., 1999). α-, β-, and γ-synucleins are also able to prevent the aggregation
of denatured proteins in vitro (Souza et al., 2000a), further supporting a conserved chaperonelike function of synucleins and the existence of several protein-protein interactions that
facilitate synaptic function.
Putative role in neurotransmitter synthesis and reuptake. Published evidence indicates that αsynuclein-mediated protein-protein interactions may modulate dopamine synthesis and
recycling. α-Synuclein may inhibit the activity of tyrosine hydroxylase (TH), the rate-limiting
enzyme in dopamine synthesis. α-Synuclein and TH co-immunoprecipitate from rat striatal
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tissue and MN9D dopaminergic cells and α-synuclein was shown to inhibit TH activity in MN9D
and PC12 cells, potentially through PP2A phosphatase-mediated reduction of serine 40
phosphorylation of TH (Peng et al., 2005; Perez et al., 2002). α-Synuclein may also interact with
and inhibit the activity of aromatic amino acid decarboxylase, which catalyzes the conversion of
L-DOPA to dopamine (Tehranian et al., 2006). Thus, α-synuclein may serve as a negative
regulator of dopamine synthesis, though further validation of these findings is necessary.
Several reports have also implicated α-synuclein in the regulation of the dopamine transporter
(DAT), though the evidence is conflicting with regards to the functional consequences. Direct
binding of α-synuclein to DAT has been demonstrated in multiple studies. However, α-synuclein
does not appear to alter DAT function, but rather in various cellular contexts can promote or
inhibit DAT trafficking to the plasma membrane (Oaks and Sidhu, 2011).

Elucidating the

relationship between α-synuclein and DAT requires further investigation.
2.4 α-Synuclein structural flexibility
Primary sequence. The primary sequence of α-synuclein consists of 140 amino acids with a
predicted molecular mass of 14,460.16 Da and an isoelectric point of 4.67 (figure 1). The
sequence of α-synuclein is composed of three functionally defined domains. The N-terminal
region (amino acids 1-60) is characterized by the presence of unique and highly conserved
sequence of imperfect tandem repeats with a central consensus motif of K(A)-T(A,V)-K(V)E(Q,T)-G(Q)-V(A). These motifs spanning residues 10-86 are projected to form two amphipathic
α-helices and are characteristic of several proteins such as apolipoproteins that bind reversibly
to membranes (George et al., 1995; Maroteaux et al., 1988). Indeed the structure of membrane
bound α-synuclein contains two α-helices (amino acids 3-37 and 45-92) in a roughly antiparallel
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arrangement with a short linking region (Ulmer et al., 2005). These helices are stabilized by
interaction with a variety of phospholipid bilayers, though α-synuclein interacts preferentially
with membranes of high curvature and an abundance of acidic phospholipids, properties
consistent with those of synaptic vesicles (Davidson et al., 1998; Zhu et al., 2003). Upon
interaction with membranes of low curvature α-synuclein adopts a distinct secondary structure
characterized by a single extended helix that includes both previously described helical domains
and the linker region (amino acids 38-44) (Ferreon et al., 2009; Georgieva et al., 2010; Trexler
and Rhoades, 2009). All known mutations associated with familial PD (A30P, E46K, H50Q, G51D,
A53E, and A53T) are found in the N-terminal domain (Krüger et al., 2008; Lesage et al., 2013;
Pasanen et al., 2014; Polymeropoulos et al., 1997; Proukakis et al., 2013; Zarranz et al., 2004).
These mutations, with the exception of G51D, A53E, and A30P, increase the propensity of αsynuclein to form insoluble aggregates and produce morphologically distinct aggregate species
(Ghosh et al., 2014; Giasson et al., 1999; Greenbaum et al., 2005; Lesage et al., 2013; MahulMellier et al., 2015; Narhi et al., 1999).

Though the precise mechanism by which these

mutations promote aggregation has not been conclusively shown, evidence implicate an
accelerated formation of oligomers (Conway et al., 2000) likely due to the destabilization of the
native N-terminal conformation (Bertoncini et al., 2005a; Burré et al., 2015; Coskuner and WiseScira, 2013; Dettmer et al., 2015).
Amino acids 61-95 compose the hydrophobic NAC domain (Uéda et al., 1993). This region
contains a sequence of amino acids (71-82) necessary and sufficient for α-synuclein selfassembly into amyloid fibrils (Giasson et al., 2001). Recently the crystal structures of residues
68-78 (termed NACore), and residues 47-56 (PreNAC) were resolved by the use of micro-
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electron diffraction, revealing that strands in this region stack in-register into β-sheets that are
typical of amyloid assemblies (Rodriguez et al., 2015).
The C-terminal domain (96-140) is rich in negatively charged amino acids (contains 10 glutamate
and 5 aspartate residues) and was originally proposed to be essential for maintaining the
solubility of the protein. The presence of 5 proline residues, which are known to induce turns
and disrupt secondary protein structure, suggested that this region is devoid of secondary
structure (George et al., 1995; Ulmer et al., 2005). However, the C-terminus was shown to form
transient, long-range interactions with the N-terminus resulting in the formation of multiple
compact monomeric structures (Bertoncini et al., 2005a; Dedmon et al., 2005).

These

compacted structures of α-synuclein are temperature sensitive and are resistant to aggregation.
The data also indicated that at elevated temperatures the C-terminus assumes an extended
conformation that liberates N-terminal associations and enables aggregation (Bertoncini et al.,
2005b; Dedmon et al., 2005). Moreover, C-terminally truncated forms of α-synuclein aggregate
faster than full length protein (Hoyer et al., 2004; Li et al., 2005). Truncated α-synuclein has
been detected in the brains of both control (non-disease) and PD patients. Cleavage of fulllength protein at residues D115, D119, N122, D125 and Y133 was documented in α-synuclein
extracted from LBs (Anderson et al., 2006).
The C-terminus appears to be important for the interaction of α-synuclein with other proteins
and for the interaction with small molecules (Burre et al., 2012; Burré et al., 2010; Conway et al.,
2001; Mazzulli et al., 2006; Souza et al., 2000b; Woods et al., 2007). Additionally, it contains the
major sites of metal binding and post-translational modifications. Binding of iron, copper, and
other metals has been shown to influence α-synuclein function and aggregation (Uversky et al.,
2001a). Addition of Fe(III), but not Fe(II) to preformed oligomers of α-synuclein accelerates
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aggregation, raising the question of metal binding at different points during the aggregation
process (Kostka et al., 2008). Cu(II) is unique among metals at accelerating aggregation of αsynuclein at physiologically relevant concentrations.

The sole histidine residue H50 in α-

synuclein was found to be critical for Cu(II) binding (Rasia et al., 2005) whereas other divalent
metal ions, including Mn(II), Co(II), Ni(II) and Fe(II), preferentially bind to the C-terminus of αsynuclein at residues D121, N122, and E123 (Binolfi et al., 2006).
Post-translational modifications.

α-Synuclein undergoes a number of post-translational

modifications, including N-terminal acetylation, serine and tyrosine phosphorylation, lysine
ubiquitination and tyrosine nitration (Oueslati et al., 2010; Barrett & Greenamayer 2015). αSynuclein purified under mild conditions is acetylated in the N-terminus.

The N-terminal

acetylation may account for the formation of an oligomeric form of the protein with partial αhelical structure (Trexler and Rhoades, 2012).

However, semisynthetic production of N-

terminally acetylated α-synuclein demonstrated that modified and unmodified versions of the
protein share similar secondary structure, aggregation propensities, and membrane binding
(Fauvet et al., 2012a). NMR studies indicated that the first 12 residues undergo a chemical shift
due to N-terminal acetylation. This modification also appears to stabilize the helicity of the Nterminus within the context of the full-length protein, and increases the affinity of α-synuclein
for lipids (Dikiy and Eliezer, 2014).
Mass spectrometry-based methodologies revealed that α-synuclein extracted from human Lewy
bodies was phosphorylated at S129 (Fujiwara et al., 2002).

An antibody raised against

phosphorylated S129 was then used to show that α-synuclein was phosphorylated at this site
only in subjects with disease and that S129 phosphorylated α-synuclein was present only in the
Triton-X- and Sarkosyl-insoluble, urea soluble fraction. These data indicated that some form(s)
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of aggregated α-synuclein and not the soluble protein is targeted for phosphorylation at S129.
Indeed in vitro data showed that purified fibrils of α-synuclein are substrates for casein kinase 1
or 2 (Waxman and Giasson, 2008). Other data indicated that polo-like kinase (PLK) 2-mediated
phosphorylation of S129 increased autophagy-mediated degradation of α-synuclein, suggesting
that phosphorylation may be a neuroprotective mechanism to accelerate clearance of
aggregated protein (Oueslati et al., 2013). In addition to the monomeric α-synuclein, S129
phosphorylated bands with apparent molecular weight of 22 kDa and 29 kDa were observed in
the detergent insoluble extract (Hasegawa et al., 2002). These bands were also immunoreactive
with anti-ubiquitin antibodies suggesting that S129 phosphorylated α-synuclein is also targeted
for mono- and di-ubiquitination. It has long been established that the core of Lewy bodies
stains positive for both α-synuclein and ubiquitin whereas the surrounding halo is
immunoreactive for α-synuclein (Hasegawa et al., 2002).

Of the 15 lysine residues in α-

synuclein, the major sites of LB-derived α-synuclein undergoing ubiquitination were residues
K12, K21, and K23 (Anderson et al., 2006; Hasegawa et al., 2002; Sampathu et al., 2003).
A number of spectroscopic methodologies (CD and NMR) were employed to explore the effect
of S129 phosphorylation on the structure of α-synuclein. CD data revealed that phosphorylation
of S129 did not affect secondary structure, such that both non-phosphorylated and
phosphorylated S129 exhibited random coil structure (Paleologou et al., 2008). NMR data
revealed a number of chemical shifts that occur due to phosphorylation. While the residues
surrounding S129 exhibited the greatest perturbation, residues 1-90 also exhibited detectable
chemical shifts (Paleologou et al., 2008) This likely reflects the previously documented longrange interactions of the C- and N-termini. The potential effects of phosphorylation of S129 on
the structure of the protein were not faithfully reproduced by mutation of S129 to either E or D,
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two common phosphomimics used to study the structural consequences of phosphorylation.
For example, phosphorylation at S129 increased the hydrodynamic radius of the protein,
whereas S129 E/D mutants did not (Paleologou et al., 2008).
Subsequent studies found additional sites of phosphorylation.

Elevated levels of

phosphorylated α-synuclein at residue S87 were detected in human brains with Alzheimer’s
disease, Lewy Body disorders, and multiple system atrophy (Paleologou et al., 2010). S87
phosphorylation alters the biophysical properties of α-synuclein, including inhibition of fibril
formation and reduction in membrane binding (Paleologou et al., 2010).

Additionally,

phosphorylated α-synuclein at residue Y125 was detected in Drosophila expressing human
wildtype α-synuclein as well as in human brains, though levels were decreased in disease
compared with aged-matched healthy controls (Chen et al., 2009).
The proximity of the α-synuclein phosphorylation sites to the metal binding sites raised the
question of how phosphorylation may affect metal ion interactions. This was investigated by
the use of C-terminal peptides containing residues 119-132 that were either unmodified,
phosphorylated at Y125 or at S129 (Liu and Franz, 2005). By exploiting the luminescence
properties of Tb3+, it was found that phosphorylated Y125 showed enhanced Tb3+ binding
relative to wildtype or phosphorylated S129. Additionally, phosphorylated Y125 preferentially
bound to trivalent rather than divalent metal ions. To investigate this further, longer C-terminal
fragments comprised of residues 107-140 that were either unmodified of monophosphorylated
at Y125 or S129 were tested for their affinity to various metal ions. By using a fluorescence
quenching assay, the dissociation constants of the metal ion complexes and the α-synuclein
peptides were determined. These data indicate that either phosphorylation at Y125 or S129
increases the binding affinity for Cu (II) and Fe(II), but not Fe(III). Furthermore, phosphorylated
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Y125 has a greater affinity for Pb(II) than wildtype, but phosphorylated S129 has an even greater
affinity than phosphorylated Y125. Additionally, tandem MS indicated that phosphorylation
causes the metal ion binding sites to shift towards the C-terminal end of α-synuclein (Lu et al.,
2011).
α-Synuclein within Lewy bodies is nitrated on all four tyrosine residues (Giasson et al., 2000).
Chemical nitration of α-synuclein results in the formation of both tyrosine nitrated monomers
and nitrated dimers (Souza et al. 2000b). Immunoelectron microscopy confirmed that nitrated
monomers and dimers are incorporated into amyloid fibrils.

Purified nitrated α-synuclein

monomer by itself was unable to form fibrils, whereas the nitrated dimer accelerated
aggregation of unmodified α-synuclein (Hodara et al., 2004). Additionally, nitration at residue
Y39 in the N-terminus decreased binding to synthetic vesicles and prevented the protein from
adopting α-helical conformation (Hodara et al., 2004).

These observations were recently

confirmed and elegantly expanded by the generation of site-specifically nitrated α-synuclein
using protein semisynthetic chemistries (Burai et al. 2015). Using the synthetic nitrated αsynuclein the data showed that nitration did not interfere with phosphorylation of S129 by PLK3
and reaffirmed that intermolecular interactions between the N- and C-terminal regions of αsynuclein are critical in directing nitration-induced oligomerization of α-synuclein (Burai et al.
2015).
Native conformation(s) of α-synuclein. Figure 2 depicts the rapid growth in the number of
publications identified in PubMed using the term synuclein and highlights key studies that
explored the native structure and conformation of the protein. Early biochemical studies of αsynuclein isolated from bacterial expression systems or α-synuclein expressed in rodent tissues
indicated that it is monomeric with limited secondary structure. Electrophoretic separation of
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α-synuclein purified without heating on 6, 10, or 14% acrylamide gels estimated an apparent
molecular weight of 20±3 kDa. However, the values of sedimentation coefficient (S20,w = 1.7S),
stokes radius (34 Å), analysis on native gels and derivation of the frictional coefficient (f/fo=2.09)
indicated an apparent molecular weight in the range 57-58 kDa (Weinreb et al., 1996). To
reconcile this apparently anomalous behavior it was proposed that monomeric α-synuclein
achieves minimal structure in simple solutions and this rather extended unstructured
conformation resembles a globular protein with a larger apparent molecular weight. This
assumption was further corroborated by examination of purified monomeric α-synuclein by CD,
FTIR and small angle X-ray scattering, which failed to identify significant secondary structural
features.

Furthermore, minimal shifts in the spectroscopic features of α-synuclein were

observed when the protein was placed in solutions that would increase hydrophobicity and
neutralize negative charges indicating that the protein is natively unstructured, joining a
growing group of proteins sharing similar biochemical and biophysical characteristics (Uversky et
al., 2001b). NMR and CD data, however, indicated that α-synuclein assumes increasingly folded
secondary structure when exposed to conditions that promote aggregation (low pH and high
temperature) or upon interaction with phospholipids. Collectively these data indicated that
native α-synuclein is primarily an unstructured monomer, which can assume different compact
conformations that resist aggregation, adopts α-helical conformation upon binding to lipids and
undergoes conformational changes prior to oligomerization and formation of amyloid fibrils
(Uversky et al., 2001b). However, the methodologies employed to quantify the molecular
weight of α-synuclein in these elegant studies were not based on first principles and therefore a
lingering uncertainty remains regarding the native size of the protein. Moreover, crosslinking
experiments in both intact cells expressing α-synuclein and lipid-free lysates revealed the
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stabilization of high molecular weight α-synuclein multimers (consistent with dimers, trimers,
and larger multimers).

These multimers were not reduced by dilution of lysates before

crosslinking, nor by reducing the concentration of crosslinker from 1 mM to 8 µM, suggesting
that they represented endogenous protein complexes (Cole et al., 2002).
Examination of the α-synuclein native state was reignited in 2011 with the publication of results
indicating that α-synuclein exists natively as a tetramer, rather than a monomer. Methodologies
that are based on first principles were employed to examine the molecular weight and size of αsynuclein extracted under non-denaturing conditions from human red blood cells. Analytical
ultracentrifugation produced a sedimentation equilibrium value of 4.78 S, indicating a molecular
weight of 57.8 kDa. Analysis of particle geometry by scanning transmission electron microscopy
revealed the presence of roughly spherical molecules with a diameter of approximately 3.0-3.5
nm. Automated sampling of 1000 α-synuclein particles showed a distribution of molecular
weights between 10 and 175 kDa with a peak distribution at 55 kDa. These findings constitute
the most direct measurements of the native molecular weight of α-synuclein. The tetrameric
species were shown to have α-helical conformation and were resistant to aggregation (Bartels et
al., 2011).
Complimentary observations were made using recombinant GST-tagged α-synuclein purified
from bacterial expression systems under non-denaturing conditions. Single-particle electron
microscopy of purified α-synuclein revealed complexes of sizes and internal geometries
consistent with trimers and dimers, which were corroborated by measurements of the
hydrodynamic radii and elution on native state PAGE. As observed previously, these species
were more resistant to aggregation than denatured monomer. CD also showed that several αsynuclein mutations associated with early onset PD (A30P, E46K, A53T) exist in less ordered
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conformations than wildtype α-synuclein. These mutants were also more prone to aggregation
(Wang et al., 2011). However, using the same α-synuclein construct that contains a 10-residue
N-terminal extension, which forms multimers when isolated from E. coli, NMR studies indicated
that only a small fraction of α-synuclein assembles into α-helical trimers and tetramers and the
majority remains as a disordered monomer (Gurry et al., 2013). These data indicated that
several potential conformers of α-synuclein may exist in equilibrium. The observation that αhelical trimers and tetramers constitute only a small fraction of the total α-synuclein may
explain other studies in which in-cell NMR was used to probe for the structure of α-synuclein
and reported primarily the presence of unstructured monomer. NMR data of α-synuclein in
intact cells failed to detect stable or highly populated α-synuclein multimers and confirmed the
intrinsically disordered nature of the protein in E. coli regardless of its purification method
(Binolfi et al., 2012).

Collectively these studies generated an apparent controversy and

stimulated several additional studies that explored the native size and structure of α-synuclein.
A re-examination of the native state of α-synuclein reasserted that the behavior of α-synuclein
from various sources was consistent with a disordered monomer. This behavior was observed
with protein extracted and isolated under both denaturing and non-denaturing conditions. CD
spectra previously attributed to tetrameric assemblies were not reproduced using isolated
monomer, but were replicated with the addition of small unilamellar vesicles. Natively isolated
α-synuclein before or after boiling that disrupts secondary structure migrated as high molecular
weight α-synuclein bands in native PAGE, which was attributed to the rather expanded size of
the unstructured monomer in solution. These findings reaffirmed that the majority of native αsynuclein is a monomer with minimal secondary structure (Fauvet et al., 2012a). Further
support was provided by similar explorations in the mouse brain, which indicated that the
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predominant native form of α-synuclein is an unstructured monomer. α-Synuclein exhibited
random coil structure in solution, readily aggregated over time, and adopted α-helical structure
only upon membrane binding (Burré et al., 2013).
α-Synuclein multimers were detected in postmortem non-diseased human brain using mild
protein extraction methods, but no further purification. These α-synuclein multimers had
Stokes radii ranging from 33.2-37.5 Å, sedimentation coefficients ranging from 1.4S to 3.8S and
apparent molecular weights ranging from 53-70 kDa in native gradient gels. The multimers were
detected by anti-α-synuclein antibodies that recognize different epitopes and the multimer
identity was confirmed by mass spectrometry. Consistent with previous observations, melting
point thermostability analysis showed progressive loss of the α-synuclein multimers and heating
of the brain extracts above 55 oC collapsed the higher molecular weight α-synuclein conformers
into the 53 kDa species, which corresponds to the unstructured monomer. These data indicated
the presence of α-synuclein conformers, defined as conformationally diverse α-synuclein
multimers, in the human brain. Therefore it appears that both monomer and metastable
multimers coexist and that interactions with lipids, other proteins, or small molecules may
transiently stabilize these species (Gould et al., 2014). This was further supported by controlled
bimolecular fluorescence complementation methodologies in different cell types that found αsynuclein metastable conformers assembled in synapses. It was suggested that the function of
these multimeric α-synuclein conformers is to restrict recycling of synaptic vesicles and thus
reduce neurotransmitter release (Wang et al. 2014).
Additional support for native multimeric species comes from recent studies in which serial
purification of α-synuclein from non-pathological human cortical tissue was performed.
Removal of lysate components other than protein followed by sequential removal of proteins
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though size exclusion, anion chromatography, and thiopropyl sepharose 6b separation, resulted
in the isolation of >90% pure α-synuclein.

Each step of serial purification resulted in a

progressive loss of α-synuclein immunoreactive high molecular weight bands observed after
disuccinimidyl glutarate crosslinking and SDS-PAGE separation.

Analysis of α-synuclein

secondary structure by CD found that the sequentially purified protein had greater α-helical
content than the recombinant α-synuclein. However, a high degree of variability in secondary
structure was observed between purified samples raising questions about the stability of these
helical conformations (Luth et al., 2015). Furthermore, crosslinking experiments conducted in
brain tissue from mice expressing wildtype or A53T human α-synuclein in the absence of mouse
α-synuclein showed that the A53T mutation reduced the presence of soluble multimeric αsynuclein (Dettmer et al., 2015).
2.5 Concluding remarks and perspectives.
Collectively the studies on the native structure indicate a remarkable conformational plasticity
and structural flexibility of α-synuclein. The ability of the protein to adopt N-terminal α-helical
conformation through its association with lipids has been well documented. The association
with lipids has been shown to prevent fibril formation (Martinez et al., 2007; Zhu and Fink, 2003)
and may also stabilize physiological multimeric species that together with the monomer
regulate SNARE complex assembly and recycling of synaptic vesicles (Burré et al., 2014; Wang et
al. 2014). However, other groups have demonstrated a role for phospholipid membranes in
promoting pathological α-synuclein aggregation, potentially by acting as a scaffold for amyloid
nucleation. This event may preferentially occur at low lipid to protein ratios, when monomeric
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α-synuclein is free in solution and can participate in nucleation (Galvagnion et al., 2015;
Ysselstein et al., 2015).
In figure 3 we propose a model which incorporates and summarizes the existing knowledge
regarding α-synuclein biology and structure. The steady state levels of α-synuclein are carefully
regulated by protein synthesis and removal by several pathways such as the ubiquitinproteasome pathways and autophagy (Webb et al., 2003). Controlling the steady state levels of
this protein by regulating synthesis and degradation may be the first critical defense in
preventing aggregation. Conformational change to α-helical rich structures, and stabilization of
metastable multimers is achieved by specific interactions with vesicular phospholipids and
proteins. The sequestration of α-synuclein in association with membrane vesicles and with
other proteins may be of critical importance for preventing aggregation. Therefore these
dynamic equilibria maintain functionality and promote assemblies that are resistant to
aggregation.

Catastrophic events that may include inappropriate post-translational

modifications will disassemble the multimers as well as transform aggregation-incompetent
monomers to aggregation-competent species. The first step in the pathway to amyloid fibril
formation is the generation of a dimer that is either held together by hydrophobic interactions
induced by increased conformational transition to β-sheet structure or upon covalent crosslinking. Following this nucleation event (Wood et al., 1999) the hydrophobic patch of amino
acids between residues 71-82 appears to be primarily responsible for allowing additional αsynuclein monomers to assemble to form oligomeric structures.

This transition is the

committed rate limiting step for aggregation and must overcome a relatively large
thermodynamic requirement that permits the conversion from an unstructured coil to organized
β-sheet conformation. Oligomers are soluble in aqueous buffers and can appear spherical or
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ring-like by atomic force and electron microscopy (Conway et al., 2000; Lashuel et al., 2002).
Soluble, high molecular weight oligomers have been extracted from human brain tissue and
their levels appear to be increased in PD brain (Sharon et al., 2003) as well as mouse models of
α-synuclein aggregation (Tsika et al., 2010). As oligomers grow, they reach an undefined critical
length and are able to assume additional quaternary structure. At this stage, these structures
may continue to grow in linear β-sheets, forming polarized protofibrils and eventually fibrils.
Fibrils may further arrange into protein inclusions although it remains unclear if other proteins
within these inclusions anchor these fibrils. Alternatively, oligomers may remain soluble by
interacting with small molecules (Conway et al., 2001) or by incorporating post-translationally
modified α-synuclein molecules. These structures remain “off the amyloid fibril pathway” and
may constitute what has been described in human postmortem tissue as “dots” or “dust-like”
amorphous aggregates (Braak et al., 2001; Duda et al., 2002). At this juncture, it remains
unclear which of these assemblies are toxic to neurons. Recent data indicate that several
conformationally distinct assemblies (possibly different strains) of α-synuclein generated in vitro
will induce the aggregation of endogenous α-synuclein resulting in neurodegeneration (Guo et
al., 2013; Luk et al., 2012; Peelaerts et al., 2015; Sacino et al., 2014). The appreciation of
different α-synuclein conformers and assemblies as well as their roles in disease may guide
potential therapeutic approaches. For example, therapeutic strategies can be centered on
preserving and stabilizing the physiological multimeric conformers as well as preventing
monomers from aggregating.

Alternatively, sequestration and removal of aggregation-

competent monomers and oligomers can be considered.
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Figure 2.1. Primary sequence of human α-synuclein. Green color indicates the
imperfect tandem repeats. Known mutations are indicated in red. The hydrophobic
NAC domain is underlined. The major sites of posttranslational modifications identified
in vivo are highlighted in blue (Ac, acetylation; Ub, ubiquitination; NO2, nitration; and
PO3- phosphorylation).
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Figure 2.2. The graph depicts the number of publications retrieved from PuBMed using
the search term “alpha synuclein” from a single publication in 1998 to 862 in 2015.
Significant milestones that examined the native structure and conformations of αsynuclein are displayed.
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Figure 2.3. Free energy landscape of possible α-synuclein conformers and multimeric
assemblies. The conversion of native α-synuclein to aggregation-competent monomers
may depend on dissociation from stabilizing interactions with lipids and/or proteins as
well as dissociation of the metastable tetrameric species. α-Synuclein aggregationcompetent monomers can then assemble into dimers and larger oligomeric conformers.
The generation of α-synuclein oligomers can rapidly lead to formation of stable amyloid
fibrils, or ‘off-pathway’ amorphous aggregates, both of which have been observed in
postmortem brain tissue from patients with PD and related disorders.
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3.1 Abstract
Aggregation of α-synuclein contributes to dopaminergic degeneration in Parkinson’s disease and
related neurodegenerative disorders. A decline in proteostasis is associated with protein
aggregation but how α-synuclein aggregation affects the brain proteome remains
undetermined. A global proteomic approach applied to wild type mouse midbrain and striatum
quantified 5,290 proteins of which 311 exhibited significant change in relative abundance in
response to α-synuclein aggregation induced by pre-formed fibril injection. These proteins were
not affected in α-synuclein null mice, which do not undergo α-synuclein aggregation or
dopaminergic neuron degeneration. Interestingly, an increase in the immunoproteasome,
which is linked with preservation of proteostasis, was documented in wild type mice and in
human synucleinopathies. The increase in immunoproteasome resulted in augmented
proteolytic activity and improved efficiency to degrade α-synuclein fibrils. The induction of the
immunoproteasome in response to α-synuclein aggregation could be exploited as a protective
strategy to preserve proteostasis in α-synuclein aggregation disorders.

3.2 Introduction
Cells have developed proteostasis networks to maintain proper protein homeostasis and to
combat potentially toxic protein aggregation1. Deficiencies in proteostasis are linked to several
diseases, including cystic fibrosis2, diabetes3, and cancer4,5. Additionally, a failure in proteostasis
associated with protein aggregation is considered a pathogenetic mechanism of several
neurodegenerative diseases of aging such as Parkinson’s disease (PD), Alzheimer’s disease (AD)
and Amyotrophic Lateral Sclerosis (ALS)6–8. The aggregated proteins in these diseases have been
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identified, including α-synuclein in PD, amyloid-β and tau in AD, and SOD1, FUS, and TDP43 in
ALS9–12. The indomitable progression of aggregation and cell death suggests that the
proteostasis network is unable to cope in these neurodegenerative diseases. However,
reorganization and reallocation of proteostatic resources may be a viable strategy to combat
toxic protein aggregation. The effects of endogenous protein aggregation on the overall
proteome have never been studied in vivo, and may uncover proteostatic responses to protein
aggregation that could be modulated to mitigate disease.
α-Synuclein is a 140 amino acid protein that has roles in synaptic plasticity and has been linked
to neurodegenerative disease13–15. Aggregated forms of the protein are deposited into
cytoplasmic inclusions known as Lewy Bodies, which are the histopathological hallmarks of PD
and several other related neurodegenerative disorders16. Recombinant wild type (WT) αsynuclein aggregates and forms amyloid-like fibrils17. Several point mutations in α-synuclein
that cause early-onset PD have been identified, including A30P, E46K, H50Q, G51D and A53T18–
22

. These point mutations accelerate aggregation, supporting the role of protein aggregation in

causing pathology23–26. Additionally, multiplications of the gene encoding α-synuclein cause
PD27–29. Collectively, these data demonstrate a role for α-synuclein aggregation in human
disease.
A recently developed mouse model of α-synuclein combines several cardinal features of PD,
including endogenous α-synuclein aggregation concomitant with progressive dopaminergic
degeneration and motor impairment30. In this model preformed fibrils (PFFs) of recombinant
WT mouse α-synuclein were unilaterally injected into the striatum of non-transgenic mice. This
induced a cascade whereby endogenous α-synuclein progressively aggregates, first in the
regions near the injection site and then to synaptically connected regions. Eventually, the mice
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exhibited dopaminergic neuron degeneration and impaired balance and motor coordination.
Importantly, dopaminergic degeneration and α-synuclein inclusions were confined to the
injected side and not found in the non-injected side of the brain. Additionally, injection of PFFs
into α-synuclein null (Snca -/-) mice failed to induce these effects, indicating that the presence
of endogenous α-synuclein was required. This PFF injection model has been successfully
reproduced in both mice31,32 and rats33.
This model (both WT and Snca -/- injected mice) provides a unique opportunity to study, in vivo,
the changes in the proteome upon aggregation of endogenous α-synuclein. To study these
proteome responses, we used mass spectrometry (MS)-based proteomics in combination with
Stable Isotope Labeling in Mammals (SILAM)34,35 to quantify changes in the relative abundance
of proteins in the brain in response to endogenous α-synuclein aggregation.

3.3 Experimental Procedures
Animals: Wild type (WT) C57BL6/C3H mice were obtained from the Jackson Laboratories (Bar
Harbor, ME). Snca -/- mice36 were maintained on a C57BL6 background.

13

C-Stable Isotope

Labeling in Mammals (SILAM) mouse brain tissue (Female, L-Lysine 13C6, 97%) was purchased
from Cambridge Isotope Laboratories, Inc. All housing, breeding, and procedures were
performed according to the NIH Guide for the Care and Use of Experimental Animals and
approved by the University of Pennsylvania Institutional Animal Care and Use Committee
(IACUC).
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Stereotaxic injection of PFFs: For stereotaxic injection, PFFs were first diluted in sterile PBS and
fragmented using a Bioruptor bath sonicator (Diagenode; Denville, NJ). Sonication was
performed at high power for 10 cycles (30s on, 30s off, at 10°C). Mice (2-3 months old) were
anesthetized with ketamine hydrochloride (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). For
each animal, PFFs were stereotaxically targeted into the ventral striatum (AP: +0.2 mm Bregma,
lateral: 2.0 mm from midline, depth: 3.6 mm beneath the dura), dorsal striatum (AP: +0.2 mm,
lateral: 2.0 mm, depth: 2.6 mm), and overlaying cortex (AP: +0.2 mm, lateral: 2.0 mm, depth: 0.8
mm). Injections were made through a single needle tract using 10 µL syringes (Hamilton, NV) at
a rate of 0.1 µL per min (2.5 µL total per site) with the needle in place for > 5 min at each target.
Animals were monitored regularly following recovery from surgery. Mice were sacrificed at 90
days post injection by overdose with ketamine/xylazine. For biochemical studies, dorsal
striatum and ventral midbrain from ipsilateral and contralateral sides were dissected and stored
at -80°C until used. For histological studies the brain and spinal cord were removed after
transcardial perfusion with PBS and underwent overnight postfixation in either neutral buffered
formalin (Fisher Scientific) or 70% ethanol (in 150 mM NaCl, pH 7.4), before being processed and
embedded in paraffin.

Immunohistochemistry: Immunohistochemistry for α-synuclein phosphorylated at Ser-129 and
tyrosine hydroxylase (TH) were performed on 6 µm thick coronal sections as previously
described30,37. Digitized images of stained sections were acquired using a Perkin Elmer Lamina
scanner at 20x magnification. Midbrain DA neurons belonging to the substantia nigra pars
compacta (SNpc) and the ventral tegmental area (VTA) were quantified from TH-immunostained
coronal sections spanning the entire extent of the midbrain (every 9th section). Immunoreactive
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neurons were counted following previously described criteria for each subgroup38. Only intact
neurons with defined nuclei were included. Statistical analysis between groups was compared
using one-way ANOVA with Tukey’s post-hoc test.

Sample Preparation for LC-MS/MS: For each mouse injected, the midbrain and striatum of the
injected and non-injected sides were dissected and kept separate. Two midbrain and striatum
regions of the injected hemisphere were combined to generate one biological sample for the
proteomic analysis. The same approach was employed for the non-injected side. Four
biological samples for WT and three for Snca -/- for each injected and non-injected side were
analyzed through the proteomic work flow depicted in Figure 3.1C. Sample preparation was
done as previously described39. Briefly, tissues were homogenized with a tissue grinder in cold
urea buffer: 8 M urea, 75 mM NaCl, 50 mM Tris HCl pH 8.0, 1 mM EDTA, 2 µg/mL aprotinin
(Sigma, A6103), 10 µg/mL leupeptin (Roche, #11017101001), 1 mM PMSF (Sigma, 78830), 10
mM NaF, 5 mM sodium butyrate, 5 mM iodoacetamide (Sigma, A3221), Phosphatase Inhibitor
Cocktail 2 (1:100, Sigma, P5726), and Phosphatase Inhibitor Cocktail 3 (1:100, Sigma, P0044).
Following 10 min centrifugation at 20,000g, protein concentration was determined by a BCA
assay (Thermo, Prod# 23235) on the supernatant and then combined with 13C-labeled brain
lysates in a 1:1 ratio (5µg:5µg) in a mini scale. Samples were reduced for 45 min with 5 mM
dithiothreitol followed by alkylation with 20 mM iodoacetamide for 45 min. Samples were then
diluted 1:4 with 50 mM Tris HCl pH 8.0 (to reduce urea concentration to 2 M), then digested
overnight with Trypsin (Promega, Cat# V5111) at 37°C overnight. 1% formic acid was added to
the digests to remove urea by pelleting. The tryptic peptides were desalted by ultraMicroSpin
Vydac C18 column (Nestgroup, Inc, cat# SUMSS18V). The peptides were analyzed by mass
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spectrometry (MS) and the data was analyzed with MaxQuant (described below). The SILAC
ratio of injected/non-injected was calculated by dividing the injected/heavy ratio by the noninjected/heavy ratio. The SILAC ratio of light/heavy generated from the MaxQuant was
converted to log2 scale and the median of the SILAC ratios therefore was calculated. If the SILAC
ratio was close to 1:1, a larger scale sample prep was performed similarly as described above.
Protein (2 mg:2 mg, heavy:light) was digested with Trypsin/Lys-C mix (Promega, Cat# V5073) at
1:25 (enzyme:protein, w:w). The peptide fragments were desalted on tC18 SepPak cartridge
(Waters, cat# WAT036815) and the peptides were lyophilized and stored in -80°C. For reverse
phase (RP)-HPLC, the peptides were reconstituted in 20 mM ammonium formate, pH 10.0.
Peptide concentration was determined by UV280 before they were separated by high-pH
reverse phase chromatography to 72 fractions detected at UV-214 nm via ACQUITY UPLC HClass instrument (Waters). Solvent A (2% acetonitrile, 5mM ammonium formate, pH10) and
solvent B (90% acetonitrile, 5mM ammonium formate, pH 10) were used to separate peptides
with a ZPRBAX 300Extend-C18 column (4.6mmx250mm, 5 Micron, Agilent). The gradient for
separation was 1mL/min flow rate as at 9 min, 100% A; 13 min, 94% A; 63 min, 71.5% ; 68.5 min,
66% A; 81.5 min, 40% A; 83 min; 0% A; at 88-120 min with 1.2mL/min with 100% A. 5% of
samples were taken and recombined in a concatenated pattern into 24 fractions for proteomics
analysis.

LC-MS/MS: Peptide digests were analyzed on a hybrid LTQ Orbitrap mass spectrometer
(Thermofisher Scientific, San Jose, CA) coupled with a NanoLC Ultra (Eksigent Technologies) as
previously described40. Briefly, peptides were separated by RP-HPLC. Mobile phase A consisted
of 1% methanol/0.1% formic acid and mobile phase B consisted of 1% methanol/0.1% formic
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acid/79% acetonitrile. Peptides were eluted into the MS at 200 nL/min with each RP-LC run
comprising a 15 min sample load at 3% B and a 90 min linear gradient from 5 to 45% B. The
mass spectrometer repetitively scanned m/z from 300 to 1800 (R = 100,000 for LTQ-Orbitrap).
FTMS full scan maximum fill time was set to 500 ms, while ion trap MSn fill time was 50 ms;
microscans were set at one. FT preview mode, charge state screening, and monoisotopic
precursor selection were all enabled with rejection of unassigned and 1+ charge states.

MS Database Searching and Data Processing: Protein identification was performed with
MaxQuant (1.5.1.2) using a mouse UniProt database. Carbamidomethyl was defined as a fixed
modification. The False Discovery Rate for peptides was set at 1%. Fragment ion tolerance was
set to 0.5 Da. The MS/MS tolerance was set at 20 ppm. The minimum peptide length was set at
7 amino acids. The requantification option was left unchecked and the match-between-runs
was turned on. For a protein to be quantified, the peptide must be identified at least once in
light and once in heavy. To calculate the injected/non-injected ratio, the heavy/non-injected
ratio was divided by the heavy/injected ratio.

Construction of the Mouse Brain Reference Proteome: To make a unified set of literature and
experimental proteins, UniProt accessions were cross-referenced by gene or protein name.
UniProt's retrieve function was used to get protein and gene names for all UniProt accessions.
For literature proteins, we selected several studies41–44 that used MS-based proteomics to
identify proteins in the unperturbed mouse brain. Proteins identified in at least 3 of 4 biological
replicates in the non-injected side of WT mice were checked for presence in the literature list
using gene and protein names rather than UniProt accessions. Genes and proteins not found in
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the experimental protein list are included as literature-only proteins. Multiple UniProt
accessions can annotate one gene or protein name.

Statistical Analyses: The Heavy/Light (H/L) ratio in the non-injected side was divided by the H/L
ratio in the injected side to compute the injected/non-injected ratio of ratios. A protein was
considered quantified in WT if this ratio of ratios was computed in at least 3 of the 4 biological
replicates; it was considered quantified in Snca -/- if this ratio of ratios was computed in all 3
biological replicates. This resulted in 5,290 proteins quantified in WT (of which 3,331 were also
quantified in Snca -/-, and 1,959 were quantified only in WT), and 3,335 proteins quantified in
Snca -/-. A separate statistical analysis was performed for these two groups of proteins. For the
3,331 proteins quantified in both WT and Snca -/-, the ratio of ratios were scaled using the
standard z-score. p-Values were determined for each protein with the z-scaled values using a
Welch’s T-Test. The Welch’s T-Test was employed rather than a simple Students T-Test because
the samples sizes between the WT and Snca -/- experiments were unequal (4 replicates in WT
and 3 in Snca -/-). p-Values < 0.05 were considered significant, yielding 201 proteins for those
quantified in both WT and Snca -/-. Of the 1,959 proteins quantified only in the WT experiments,
the H/L ratios in the injected side and the H/L ratios in the non-injected sides were scaled using
the standard z-score. A paired Student’s T-Test was performed to calculate p-values, comparing
the injected to non-injected sides. p-Values < 0.05 were considered significant, resulting in 110
proteins. Thus the relative abundance of a total of 311 proteins were found to significantly
change (201 from those quantified in WT and Snca -/-, and 110 from those only quantified in
WT).
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Heat Map Generation: Heat maps are undirected clustering of experimental values, z-scaled
ratio of ratios with a p-value < 0.05. Heat maps were created using pHeatmap in Rstudio
(version 1.0.8). Clustering distances were calculated by row and column with Euclidean math
and clustered by the Ward.D2 methodology. The scale and intensity of color, blue to white to
red, is representative of the direction and degree of differential expression.

Mouse Immunoblot Analysis: Mouse brain samples were extracted using the same method
described above for the MS analysis. For each analysis, 5-20 μg of sample was added per lane
and separated in a 12% Bis-Tris Pre-Cast gel (ThermoFisher) and transferred to a PVDF
membrane and blocked using 7.5% BSA in TBS. Primary antibody (Table 3.1) was used
overnight. Antigens-antibody complexes were detected using an Odyssey LC scanner (LiCor)
after incubation with appropriate secondary antibodies. Densitometry was used to quantify
intensity of protein bands.

Gene Ontology Enrichment Analysis: DAVID Bioinformatics Resources 6.7 was used for
enrichment analysis. The 5,290 proteins quantified in WT were used as background. The 311
significantly changed proteins were separated into the 159 that decreased and the 152 that
increased. Each was separately used as a list and the enrichment of Biological Processes was
examined. Those with p-values < 0.05 were considered significant, and fold-changes were
determined using the DAVID software.

Cellular Compartment Localization Analysis: The 159 and 152 proteins that significantly
decreased and increased, respectively, were separately entered into UniProtKB/Swiss-Prot to
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obtain the subcellular localizations. Percentages of proteins mapped to each cellular
compartment were calculated by dividing the number of proteins mapped to a given cellular
compartment by the total number of annotated proteins entered.

Human Immunoblot Analysis: Human brain samples were extracted using high salt buffer
containing 1% Triton-X100 (150 mM NaCl, 50 mM Tris, pH 7.6). Brain samples from Dementia
with Lewy Bodies and non-disease brain were obtained45. Protease inhibitors were added to
buffer prior to use. To collect triton-soluble fractions, samples were homogenized, sonicated
and sedimented at 15,000 rpm for 30 min. 500 μl of buffer was added to each sample. Protein
concentrations were determined by BCA assay (Thermo Fisher). Samples were separated in a
12% Bis-Tris Pre-Cast gel (ThermoFisher) and transferred to a PVDF membrane and blocked
using 7.5% BSA in TBS. For each analysis 40 μg of sample was added per lane. Primary antibody
(Table SX) was used overnight. Antigen-antibody complexes were detected using LiCor after
incubation with appropriate secondary antibodies. Densitometry was used to quantify intensity
of protein bands.

Proteasome Activity Assay: Human brain samples were extracted using high salt buffer
containing 1% Triton-X100 (150 mM NaCl, 50 mM Tris, pH 7.6). Protease inhibitors were
excluded from buffer. To collect triton-soluble fractions, samples were homogenized, sonicated
and sedimented at 15,000 rpm for 30 min. 500 μl of buffer was added to each sample. Protein
concentrations were determined by BCA assay (Thermo Fisher). Proteasome Activity
Fluorometric Assay Kit (BioVision K245) was used to assay proteasome activity. Assays were
performed in a 96-well plate at 37°C according to the manufacturer’s protocol. 5 μg of lysates
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were added per experimental condition. Each condition was done with or without proteasome
inhibitor. At the final time point (60 min), the fluorescence with inhibitor was subtracted from
the fluorescence without inhibitor per condition. Three biological replicates were quantified for
each experimental condition.

In Vitro Degradation Assay: Recombinant human WT α-synuclein was purified as previously
described46. Purified human WT α-synuclein was aggregated at 5 mg/ml for 7 days at 1,400 rpm
at 37°C. The fibrils generated from the aggregation of α-synuclein were used as substrate for
the in vitro degradation assays. Myelin Basic Protein (Sigma M1891) was used at 25 μM and αsynuclein was used at 1 mg/ml. Human Immunoproteasome 20S (Enzo BML-PW8720) and
Human Constitutive Proteasome 20S (Enzo BML-PW9645) were used at a ratio of 0.11:1
proteasome:α-synuclein. Human Proteasome Activator 11S complex (BML-PW9420) was added
at a final concentration of 500 nM. Reactions were incubated at 37°C agitating at 600 rpm, and
samples were removed at indicated time points. Samples were separated in a 12% Bis-Tris PreCast gel (ThermoFisher) and stained with colloidal blue. Densitometry was used to quantify
protein degradation of monomer bands of α-synuclein. Initial time point was considered 100%
for each experimental condition. Three biological replicates were quantified for each
experimental condition.

In Vitro Aggregation Assay: Reactions from the in vitro degradation assay were stopped by
freezing samples and storing at -20°C. These samples were thawed, and used as templates by
adding 5% of these samples to soluble recombinant human WT α-synuclein. At indicated time
points, sample was removed and centrifuged at 15,000 rpm for 30 minutes at -4°C. Supernatant
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was removed and equal volume PBS was added to pellet and re-suspended. Samples were
loaded onto a 12% Bis-Tris Pre-Cast gel (ThermoFisher) and stained with colloidal blue.
Densitometry was used to quantify monomer bands of α-synuclein. Protein in the supernatant
at initial time point was considered 100% soluble. Three biological replicates were analyzed for
each experimental condition.

Table 3.1: List of Antibodies

Protein
NSE
α-Synuclein
Lmp7
β5
PKC-β2
DAT
Addc
Akt
Tyrosine
Hydroxylase

Catalog
Number
ab53025
D37A6
ab3329
PA1-977
Ab33206
MAB369
Ab3905
9272

Working
Dilution
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000

657012

1:1000

3.4 Results
Mouse Model of Endogenous α-Synuclein Aggregation
To identify proteomic perturbations induced by the aggregation of endogenous α-synuclein, a
modified version of a recently developed and independently verified mouse model30 was
employed whereby α-synuclein pre-formed fibrils (PFFs) were unilaterally injected into three
locations (cortex, dorsal and ventral striatum) of non transgenic mice. The injection of PFFs into
the WT mouse brain induces progressive aggregation of endogenous mouse α-synuclein that is
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associated with loss of dopamine producing neurons in the injected side. To confirm conversion
of endogenous α-synuclein occurred, the substantia nigra was stained with an antibody that
recognizes phosphorylated α-synuclein at Ser-129 (Figure 3.1A), a marker of α-synuclein
inclusions in human synucleinopathies47,48. In WT mice 90 days post injection, dense Lewy bodylike inclusions immunoreactive for phosphorylated Ser-129 were abundant in the injected side
but not detectable in the contralateral, non-injected side. Additionally, biochemical extraction
of brain lysates showed increased levels of insoluble α-synuclein in the injected side of the WT
mice compared with the non-injected side, corroborating the phosphorylated Ser-129 staining
and reaffirming that α-synuclein aggregation occurred in the injected side of WT mice
(Supplementary Figure 3.1).
Progressive aggregation of α-synuclein and dopaminergic degeneration has been documented in
WT but not in Snca -/- mice that are injected in the same manner with PFFs30. To confirm this in
triple-injected mice, staining was also performed in Snca -/- mice. As expected, no staining for
phosphorylated Ser-129 α-synuclein in the injected or non-injected sides was observed in the
substantia nigra of Snca -/- mice (Figure 3.1A). Thus, Snca -/- mice are an important control that
enables us to separate the effect of changes in the mouse brain proteome due to PFF injection
from those due to α-synuclein aggregation and neuron loss.
Tyrosine hydroxylase (TH) staining in both the injected and non-injected sides of WT mice was
performed in order to quantify the loss of dopaminergic neurons (Figure 3.1B). Quantification
of TH+ neurons in the substantia nigra of WT mice revealed a 19% loss in the injected versus
non-injected side that approached statistical significance (p-value = 0.0507). Quantification in
Snca -/- mice, on the other hand, revealed no significant TH+ neuron loss in the injected side.
Collectively these data indicate that α-synuclein aggregation is predominantly occurring in the
67

injected side of WT mice, leading to TH+ neuron loss, consistent with previous findings using this
model30.

Midbrain Proteome Depth, Quantification and Quality
To quantify the changes in the relative abundance of proteins in both the WT and Snca -/- mice,
we employed a quantitative proteomic workflow depicted in Figure 3.1C. The method
incorporated the use of 13C-Stable Isotope Labeling in Mammals (SILAM)34,35 as an internal
standard for the quantitative analysis of the relative abundance of proteins. Four biological
replicates for the injected and non-injected sides for the WT mouse and three biological
replicates for each side of the Snca -/- mice were analyzed. Combined analysis of the replicates
in WT mice applying a false discovery rate of 1% resulted in the identification of 7,021 proteins
in the injected side, 6,949 proteins in the non-injected side, with 6,706 proteins identified in
both sides (Figure 3.1C, Supplementary Table 1). Analysis in the Snca -/- mice resulted in the
identification of 4,739 proteins in the injected side, 4,913 proteins in the non-injected side, with
4,446 proteins identified in both sides (Figure 3.1C; Supplementary Table 2).
For a subset of the proteins identified we also detected the cognate isotopically labeled peptide,
allowing the determination of the heavy/light (H/L) ratio. The H/L ratio of 5,623 proteins in the
injected side (Supplementary Table 3) and 5,588 proteins in the non-injected side of WT mice
were obtained (Supplementary Table 4). In Snca -/- mice, the H/L ratio for 3,519 proteins in the
injected side (Supplementary Table 5) and 3,625 proteins in the non-injected side was
determined (Supplementary Table 6). We employed a ratiometric method (dividing the H/L
ratio of the non-injected side by the H/L ratio in the injected side) to quantify changes in the
relative abundance of proteins in the injected side compared with the non-injected side.
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Completion of this analysis resulted in the quantification of the relative abundance of 5,290
proteins in WT (Supplementary Table 7) and 3,335 proteins in Snca -/- (Figure 3.1C;
Supplementary Table 8).
Construction of a global mouse brain proteome was completed and used as a reference to
determine whether the proteins quantified are reflective of the proteins expressed in the mouse
brain (Supplementary Table 9). For the reference proteome we combined proteins identified by
mass spectrometry in the unperturbed mouse brain from several existing studies that we then
curated through UniProt with the 6,949 proteins identified in our study in the WT non-injected
side. This reference proteome is comprised of 11,055 proteins, of which 76 were proteins
contributed by our study.
To evaluate the quality of the quantified proteome (5,290 proteins in WT and 3,335 proteins in
Snca -/-), we compared these proteins with this reference mouse brain proteome. The
distribution of the quantified proteins based on their molecular weight was representative of
the whole mouse brain proteome covering the entire range of >10 kDa to >400 kDa (Figure
3.1D). Gene set enrichment using biological process and KEGG Pathways revealed a compatible
distribution of the quantified proteome among major biological processes with the whole brain
proteome (Figure 3.1E). Moreover, Gene Ontology enrichment analysis using cellular
components showed that the cellular location of the quantified proteins was representative of
the whole mouse brain proteome (Figure 3.1F). Collectively, these analyses suggest that the
proteins quantified here are representative of the proteins in the mouse brain.

Statistical Analysis of Proteomic Changes
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The frequency distribution of quantified proteins in WT and Snca -/- each showed a unimodal
distribution centered at Log2=0 (Figures 3.2A and B). To identify the proteins that exhibited a
significant change in relative abundance due to α-synuclein aggregation, the following statistical
analyses were performed. For the 3,331 proteins quantified in both WT and Snca -/-, the ratio
of ratios were z-scaled and a Welch’s T-Test was applied to compute p-values. (Figure 3.2C).
Using a p-value of less than 0.05, 201 proteins were significantly changed. For the 1,959
proteins that were quantified in WT only, a paired Student’s T-Test was used to compare the
injected to the non-injected side, and any p-values less than 0.05 were accepted as significant,
totaling an additional 110 proteins. Combined, this resulted in 311 proteins (152 that increase
and 159 that decrease in the injected side) that the relative abundance changed significantly
due to α-synuclein aggregation (Supplementary Table 10). A summary of the breakdown of
these 311 proteins is depicted in Supplementary Figure 3.2.
Heatmaps generated for the significant proteins quantified in both WT and Snca -/- show that
proteins with increased or decreased relative abundance in the injected side cluster together in
WT versus Snca -/- across all biological replicates (Figure 3.2D). The scale and intensity of color,
blue to white to red, is representative of the direction and degree of differential expression.
Furthermore, this clustering persists in the injected versus non-injected side for those proteins
quantified only in WT (Figure 3.2E). These data demonstrate the consistency in the relative
abundance changes of the 311 proteins across all biological replicates.

Validation of the Proteomic Changes
The documented 19% loss of TH+ neurons in the injected side of WT mice (Figure 3.1B) provides
a benchmark whereby proteins selectively expressed in dopaminergic neurons can be leveraged
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to validate the quantified changes in the proteome. Indeed four of the 159 proteins that
significantly declined in the injected side were TH, aromatic-L-amino-acid decarboxylase (Addc),
synaptic vesicular amine transporter-2 (VMAT2), and dopamine transporter (DAT) (Figure 3.3A
and B). These four proteins are selectively expressed in dopaminergic neurons and participate
in the biosynthesis, vesicular transport and recycling of dopamine. The levels of Slc10a4, a
protein that is specifically expressed in catecholaminergic neurons though its function is not well
understood, also declined in the injected side49,50. Notably, the relative abundance of proteins
such as monoamine oxidase A (MAO-A) and catechol-O-methyl transferase (COMT), that are
expressed in glial cells as well as dopaminergic neurons, varied from 6.0-6.2% and did not
change significantly (Figure 3.3B). These findings demonstrate the sensitivity and precision of
our method used to quantify relative changes in protein abundance.
The changes in the levels of TH, DAT, and Addc quantified by SILAM-MS-based methodology
were further validated by semi-quantitative western blot analysis. The western blot analysis
was entirely consistent with the MS-based quantification showing a decline of 33-51% in the
levels of TH, DAT, and Addc in the injected versus the non-injected side (Figure 3.3C).
Importantly, and consistent with the need of endogenous α-synuclein aggregation for the loss of
dopaminergic neurons, the levels of TH, DAT, and Addc do not decline in the injected side of
Snca -/- mice quantified by either the MS-based or western blot methods (Figure 3.3B and C).
Additional confirmation and validation of the MS-based quantification was obtained by probing
for proteins such as α-synuclein, NSE, PKC-β2 and Akt, which showed no change in the levels
between injected and non-injected side (Figure 3.3D; Supplementary Figure 3.3). Overall, these
findings provide confidence that the quantitative methodology delivered robust and precise
changes in the proteome in this model of endogenous α-synuclein aggregation.
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Enrichment Analysis of α-Synuclein Responsive Proteins
Enrichment analyses were performed to examine the effects of α-synuclein aggregation and
dopaminergic degeneration on biological processes within the midbrain and striatal proteomes.
The analysis used the 5,290 proteins quantified in WT mice as background and was separately
performed for the 159 and 152 proteins whose relative abundance decreased or increased,
respectively. Subcellular localizations of the significantly changed proteins were analyzed using
UniProtKB/Swiss-Prot to retrieve the Gene Ontology-annotated cellular compartments.
Cytoplasmic proteins accounted for the greatest percent, with 52% and 65% of the significant
proteins that increased or decreased, respectively (Figure 3.4A). The cell membrane accounted
for 44% of each dataset, and the nucleus for 29% and 27% (note that each protein can have
more than one localization). The mitochondria, endoplasmic reticulum, Golgi apparatus, and
extracellular space accounted for 6%-10% of the datasets. This analysis indicates that the
proteomic disturbances are impacting all major cellular compartments, although endogenous αsynuclein aggregates are predominantly cytoplasmic.
Consistent with dopaminergic neuron loss, catecholamine metabolism was a functional category
enriched by 15 fold among the proteins whose relative abundance decreased (Figure 3.4B).
Furthermore, ion transmembrane transport, microtubule organization, and vesicle-mediated
transport were all significantly enriched by 2-7 fold. The enrichment of these biological
processes suggests that cellular communication, membrane conductance, and cytoskeletal
dynamics may all be disrupted. Importantly, these functions have all been previously linked to
α-synuclein aggregation51–56, reinforcing the robustness of the quantitative approach used in our
analysis of proteome wide changes.
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Of the proteins that increased in the injected side, glycoprotein metabolism, mRNA transport
and the immune response were significantly enriched by 4-6 fold. Interestingly, the four
proteins that displayed the greatest increase in relative abundance among the 311 significant
proteins are functionally linked to immune responses.
Finally, a global pathway analysis of the 311 significantly changed proteins was performed using
the Reactome pathway database (Figure 3.4C). This analysis highlighted and confirmed the
enrichment of several distinct pathways within vesicle mediated transport, programmed cell
death, gene expression, neuronal expression and the immune system. Given that the immune
response was identified in both the biological enrichment analysis and this pathway analysis, we
further investigated its role in α-synuclein aggregation.

α-Synuclein Aggregation Upregulates the Immunoproteasome
The novel finding that Lmp7 is the protein with the highest relative abundance increase was
probed further because Lmp7 is one of the three subunits that comprise the catalytic core of the
immunoproteasome57. The immunoproteasome is an altered form of the constitutive
proteasome that is upregulated in response to interferon-gamma (IFNγ) and exhibits different
peptide cleavage activity58–61 than the constitutive proteasome. It has been proposed as an
adaptive response for the maintenance of proteostasis upon protein aggregation and has been
implicated in other neurodegenerative diseases, including Huntington’s disease62 and AD63,64,
but not in α-synuclein aggregation disorders.
The increase in relative abundance of Lmp7 quantified by the proteomic analysis was validated
by western blot analysis (Figure 3.5A). We then examined whether a similar increase of the
immunoproteasome occurs in human disease characterized by aggregation of α-synuclein. The
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levels of Lmp7 in the brains of dementia with Lewy Bodies (DLB), which contain aggregated αsynuclein, and control non-disease subjects were evaluated by semi-quantitative western blot
analysis. The analysis documents a 2-fold increase in the levels of Lmp7 in DLB as compared to
controls (Figure 3.5B). To further evaluate if the increase in protein levels correlates with
activity, chymotrypsin-like activity, which is selectively elevated in the immunoproteasome, was
quantified (Figure 3.5C). Indeed, an 80% increase in the chymotrypsin-like activity was
measured in the DLB brain homogenates as compared with controls. These data demonstrate
that the activation of the immunoproteasome quantified in response to α-synuclein aggregation
in the WT mouse also occurs in human disease driven by α-synuclein aggregation.

The Immunoproteasome Degrades α-Synuclein Fibrils
Since the immunoproteasome and constitutive proteasome have different proteolytic activities,
the possibility that the immunoproteasome and the constitutive proteasome differ in their
ability to degrade α-synuclein fibrils was evaluated. First, myelin basic protein (MBP), a protein
previously shown to be degraded more efficiently by the immunoproteasome than the
constitutive proteasome61, was incubated with purified immunoproteasome or constitutive
proteasome. After 22 hours, 96% of MBP was degraded by the immunoproteasome compared
with 69% by the constitutive proteasome (Supplementary Figure 3.4). These data document the
previously known differential activity of the immunoproteasome compared with the constitutive
proteasome and enable us to compare the catalytic efficiency against α-synuclein fibrils.
α-Synuclein fibrils were generated by a standard protocol that included continuous agitation of
soluble α-synuclein at 37°C at 1,400 rpm for 7 days. These aggregates exhibited an increase in
Thioflavin-T fluorescence (Supplementary Figure 3.5A), turbidity (Supplementary Figure 3.5B)
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and sedimentation analysis revealed a shift from the supernatant to the pellet (Supplementary
Figure 3.5C). Finally, circular dichroism revealed typical β-sheet secondary structure
(Supplementary Figure 3.5D). These amyloid-like fibrils were used as a substrate for the
constitutive proteasome, and the immunoproteasome. (Figure 3.5D). After 7 days of incubation,
100% of α-synuclein fibrils were degraded by the immunoproteasome compared with 57% by
the constitutive proteasome. Thus, the immunoproteasome degrades α-synuclein fibrils more
rapidly compared with the constitutive proteasome in a cell-free system.
Next the products of these degradation reactions were tested for their ability to accelerate the
aggregation of recombinant human α-synuclein. Intact preformed α-synuclein fibrils, the
constitutive proteasome products or the immunoproteasome products were added to soluble
monomeric α-synuclein and an aggregation reaction was performed. Typically, addition of 5%
PFFs in a solution of monomeric α-synuclein accelerates the aggregation as compared with no
PFFs as shown in Figure 3.5E. Similar with α-synuclein fibrils, addition of products generated by
the constitutive proteasome accelerated the aggregation of monomeric α-synuclein. In
contrast, the products from the degradation of α-synuclein fibrils by the immunoproteasome
did not accelerate the aggregation of monomeric α-synuclein. After 2 days of incubation, 90%
of the monomeric α-synuclein had aggregated in the presence of products derived from the
constitutive proteasome as compared to 66% from the immunoproteasome (Figure 3.5E). These
data indicate the immunoproteasome degrades α-synuclein fibrils to generate products that will
not template and accelerate the aggregation of soluble α-synuclein.
3.5 Discussion
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The proteostasis network consists of integrated cellular machinery that coordinates activities
against the harmful effects of aging, environmental stresses, and infections1. Dynamic
regulation of proteostasis pathways in response to disease-associated protein aggregation is
crucial to maintaining cellular homeostasis7,65–67. This regulation is achieved through altering
protein expression, turnover, localization, and post-translational modifications. Despite
recognition of the importance of proteostasis networks, it remains unknown how the proteome
responds to protein aggregation in neurodegenerative diseases. Here, we utilize α-synuclein, a
protein that aggregates in a spectrum of neurodegenerative diseases13–15, to quantitatively study
proteostatic regulation of the proteome in response to endogenous protein aggregation.
The present study quantified the changes in relative abundance of proteins in response to
endogenous aggregation of α-synuclein in the mouse brain using a quantitative proteomics
approach. A mouse model of endogenous α-synuclein aggregation caused by the intrastriatal
injection of pre-formed fibrils (PFFs) of α-synuclein was used30. In this model, at 90 days post
injection α-synuclein pathology and dopaminergic degeneration is restricted to one side of the
mouse brain, allowing us to use the non-injected side as an internal control. Furthermore, αsynuclein-null mice (Snca -/-) fail to develop any pathology, providing a control for proteome
responses to the injection of PFFs alone. Our quantitative proteomic approach was both
comprehensive and selective. We compared the 5,290 and 3,335 proteins we quantified in WT
and Snca -/-, respectively, to a mouse brain reference proteome that we constructed by curating
previous mass spectrometry-based studies. This analysis revealed that the proteins quantified
here do not substantially differ from previously identified proteins, demonstrating that there is
no significant bias in our quantified proteome. Critically, proteins participating in dopamine
synthesis and transport were among the 311 proteins whose relative abundance significantly
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changed. Given the documented degeneration of dopaminergic neurons in this model, this
provides confidence for our approach. If mice analyzed 180 days post injection were analyzed,
we would expect to document a similar set of proteins whose relative abundance significantly
changed, along with greater dopaminergic neuron loss.
The data revealed that Lmp7, one of the three cardinal subunits of the immunoproteasome,
exhibited the greatest increase in relative abundance in response to α-synuclein aggregation.
The immunoproteasome is a derivative of the constitutive proteasome that is upregulated
primarily by IFNγ and in response to pro-inflammatory stimuli57,68. The immunoproteasome is
formed via the replacement of the three catalytic subunits of the constitutive proteasome, β1, β2
and β5, with the three catalytic subunits of the immunoproteasome, namely Lmp2, MECL-1 and
Lmp7, respectively57. The primary function of the immunoproteasome is the generation of
peptides that are presented by MHC class I molecules on the cell surface for recognition by
CD8+ T cells69. Mice deficient in all three catalytic subunits of the immunoproteasome had
substantially reduced presentation of the majority of MHC class I epitopes during viral infection
as compared with WT mice70. The reduced presentation and differences in the repertoire of
MHC class I antigens contributed to the rejection of wild type splenocytes by the triple knockout
mice, which were otherwise healthy, viable and fertile70. The vast differences in the peptides
detected by mass spectroscopy in the presence versus the absence of the immunoproteasome
are consistent with previous reports indicating altered enzyme kinetics and cleavage site
preferences for the immunoproteasome71. The immunoproteasome usually cleaves proteins
after nonpolar residues, resulting in the generation of peptides with hydrophobic C-terminal
residues that preferentially interact with and are transported to plasma membranes by MHC
class I molecules72–74. Additionally, there is elevated chymotrypsin-like activity relative to the
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constitutive proteasome71.
Although the importance of the immunoproteasome for the host-mediated antiviral immune
response is clearly documented, additional proposed functions of the proteasome are currently
debated. Critical for neurodegenerative disorders is the debate regarding the function of the
immunoproteasome in the degradation of ubiquitinated proteins, which result from oxidative
protein modifications75–77. The association between oxidized proteins and increased
immunoproteasome has been reported78 and oxidative stress has been considered in the
pathological cascade of neurodegenerative diseases including PD and related α-synuclein
aggregation disorders79,80. However, a link between upregulation of the immunoproteasome in
response to endogenous α-synuclein aggregation, potentially mediated by oxidative stress, has
not been made. In this study, we report elevated levels and activity of the immunoproteasome
in the DLB brain compared with healthy brain (Figures 3.5B and C). Moreover, mass
spectrometry-based analysis documents a similar increase in Lmp7 in mouse brain undergoing
endogenous α-synuclein aggregation. Data in Figure 3.5D demonstrates that the
immunoproteasome has an enhanced ability to degrade α-synuclein fibrils compared with the
constitutive proteasome. Furthermore, we found that the products derived for the degradation
by the immunoproteasome are unable to accelerate the aggregation of soluble α-synuclein
(Figure 3.5E).
Immunoproteasome levels and activity were also found to be elevated in postmortem brains of
patients with Huntington’s and Alzheimer’s disease62–64. In Huntington’s disease Lmp2-positive
staining was predominantly within neurons and overlapped with approximately 5% of cortical
huntingtin protein aggregates62. In the Alzheimer’s disease increased labeling for
immunoproteasome was associated with reactive glia that surrounded amyloid-β plaques64.
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Collectively these studies suggest that coordinated and reversible activation of
immunoproteasome may influence the progression of neurodegenerative disorders and aging
consistent with the observation that primates and mice with longer lifespans have elevated
levels of the immunoproteasome81.
Of interest is the recent report documenting expression of MHC I in dopaminergic neurons in
control (non-disease) and PD post mortem tissues82. Moreover, the same report showed that
the expression of MHC I in murine dopaminergic neurons was induced by IFNγ and by oxidative
stress. These data in part corroborate our findings indicating induction of the
immunoproteasome in the substantia nigra and striatum. This report proposes a mechanism
linking neuroinflammation, MHC I expression and dopaminergic degeneration. Aggregated αsynuclein activates microglia leading to the release of IFNγ that induces neuronal expression of
MHC I. Additionally, cytosolic dopamine causes oxidative stress that contributes to MHC I
expression. This MHC I is then loaded with antigens and presented on the cell surface for
detection by cytotoxic T cells (CTLs), resulting in the selective destruction of dopaminergic
neurons. What is missing from this model is how the IFNγ or oxidative stress causes antigen
loading onto MHC I molecules for CTL detection. Our data here provide this link. Upon
stimulation by IFNγ from microglial and/or oxidative stress from cytosolic dopamine levels,
dopaminergic neurons express the immunoproteasome. The immunoproteasome is then able
to degrade α-synuclein more efficiently than the constitutive proteasome, leading to the
generation of distinct peptides that may preferentially be loaded onto MHC I. Thus, the
degradation of α-synuclein by the immunoproteasome may accelerate cell death by CTLs and
thus exacerbate dopaminergic degeneration.
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Overall, we establish a role for the immunoproteasome in disease driven by α-synuclein
aggregation. Ultimately, modulation of the immunoproteasome may have therapeutic potential
in mitigating α-synuclein-mediated neurotoxicity.
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Figure 3.1. Quantitative Proteomic Workflow and Characterization of WT and Snca -/Injected Mice.
(A) Staining the substantia nigra of the injected and non-injected sides of WT and Snca -/mice for phosphorylated α-synuclein at Ser-129, a marker for pathology.
(B) Staining for tyrosine hydroxylase in the injected and non-injected hemispheres of WT
mice (n=4; p-value = 0.0507) and Snca -/- mice (n=1).
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(C) Overview of proteomic workflow. The midbrain and striatum of each side of the mouse
brain were dissected and combined. The injected and non-injected sides were kept separate
and processed throughout the workflow independently.
(D-F) A mouse brain reference proteome was constructed by combining proteins identified
by mass spectrometry in the mouse brain in the literature with proteins we identified in the
WT non-injected side. This was compared with the proteins we quantified in both WT and
Snca -/- to secure that there are no significant biases based on protein MW (D), biological
functions (E) or cellular compartments (F).
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Figure 3.2. Analysis of Quantified Proteins and Identification of α-Synuclein
Responsive Proteins.
(A) Frequency distribution plot of proteins quantified in WT mice.
(B) Frequency distribution plot of proteins quantified in Snca -/- mice.
(C) Schematic depicting methodology to identify the significantly changed proteins. Of the
3,331 proteins quantified in both WT and Snca -/-, 201 significantly changed. Of the 1,959
proteins quantified in WT only, 101 significantly changed. Collectively, this analysis reveals
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that the relative abundance of 311 proteins significantly changed, due to endogenous αsynuclein aggregation.
(D) Heatmap depicting clustering of significantly changed proteins comparing WT to Snca /-.
(E) Heatmap depicting clustering of significantly changed proteins comparing injected to
non-injected sides in WT.
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Figure 3.3. Validation of Changes in Dopamine Neuron Specific Proteins.
(A) Depictions of a dopaminergic neuron synapse and specific proteins expressed in presynaptic dopaminergic neurons.
(B) Selective loss of these neurons results in a significant decrease in the levels of TH, DAT,
Addc and VMAT2 documented by the mass-spectrometry-based proteomic quantification.
(C) Western blot confirmation of proteins found to significantly decrease in WT but not
Snca -/- mice.
(D) Western blot confirmation of proteins found to not significantly change, including NSE,
PKC-β 2 and Akt.

89

A

B

C

Figure 3.4. Enrichment Analysis of α-Synuclein Responsive Proteins.
(A) Percent of α-synuclein responsive proteins that either increased or decreased in the
injected side that are localized to each subcellular localization.
(B) Biological processes that are significantly enriched among the α-synuclein responsive
proteins that increased or decreased in the injected side. The 5,290 proteins quantified in
WT were used as background to determine enrichment.
(C) Overview of pathways enriched for α-synuclein responsive proteins. Yellow lines
represent pathways enriched for these proteins.
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Figure 3.5. The Immunoproteasome is Implicated in Human Disease Driven by αSynuclein Aggregation.
(A) Western blot in WT and Snca -/- mouse brain for Lmp7 reveals that Lmp7 is increased
in the injected side by 226% compared to the non-injected side, consistent with the 236%
increase found by the proteomic analysis. Lmp7 was not detected in Snca -/- mice by either
Western blot or proteomics.
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(B) Western blot analysis in human DLB brain versus healthy brain reveals that Lmp7 is
increased by 297% in disease compared with healthy.
(C) Chymotrypsin-like activity, a proxy for immunoproteasome activity, is increased by
189% in disease brain compared with healthy brain. n=3.
(D) Degradation efficiencies of α-synuclein fibrils by the constitutive proteasome and the
immunoproteasome were compared. After 7 days, 100% degradation was achieved by the
immunoproteasome compared with only 55% by the constitutive proteasome. n=3.
(E) Efficiency of accelerating aggregation of the products from the degradation assay of the
immunoproteasome and constitutive proteasome were compared with 5% fibrillar PFFs
and no PFFs. n=3. Two-way ANOVA analysis with a Bonferroni post-test (*** p-value <
0.001).

92

Supplementary Figure 3.1. Greater Insoluble α-Synuclein in the Injected Side than the
Non-Injected Side.
Sequential biochemical extraction was performed on the combination of the midbrain and
striatum from the injected and non-injected sides of the WT mouse. Samples were analyzed
by Western blot to confirm that there is a greater amount of α-synuclein in the SDS-Soluble
fraction in the injected side than the non-injected side.
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Supplementary Figure 3.2. Breakdown of 311 α-Synuclein Responsive Proteins.
All 5,290 proteins quantified in WT were analyzed to identify significantly changed
proteins.

Supplementary Figure 3.3. Relative Abundance of α-Synuclein Does Not Change in
WT.
Western blot confirmation of the relative abundance of α-synuclein in the injected and noninjected sides from WT mice.
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Supplementary Figure 3.4. Myelin Basic Protein is More Rapidly Degraded by the
Immunoproteasome than the Constitutive Proteasome.
(A) Myelin Basic Protein was incubated with the constitutive proteasome or the
immunoproteasome. At indicated time points aliquots were removed and analyzed by SDSPAGE.
(B) Densitometry of monomeric band of MBP reveals that incubation with the
immunoproteasome results in 96% degradation compared to 70% with the constitutive
proteasome. n=3.
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Supplementary Figure 3.5. Amyloid Characteristics of α-Synuclein Fibrils Used for
Pure Proteasome Assay.
(A) Human recombinant WT α-synuclein was incubated at 37°C, agitating at 1,400 rpm at 5
mg/ml. At Day 0 and Day 7 sample was removed for Thioflavin-T analysis, an assay for the
presence of β-sheet rich amyloid fibrils, revealing a >20-fold increase in fluorescence.
(B) At Day 0 and Day 7 a sample was removed for turbidity analysis, an assay for the
presence of insoluble species, revealing a >30-fold increase in turbidity.
(C) At Day 0 and Day 7 a sample was removed for sedimentation analysis, revealing a shift
of protein from the soluble supernatant to the insoluble pellet.
(D) At Day 7, circular dichroism analysis was done. The monomer displayed random coil,
and both the fibrils and PFFs revealed β-sheet structure.
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4.1 Abstract
α-Synuclein deposited into Lewy Bodies in Parkinson’s disease and related synucleinopathies
have elevated levels of Ser-129 phosphorylation compared with soluble protein. This change
may be reflective of a global perturbation in cellular signaling induced by α-synuclein
aggregation that contributes to neurodegeneration and disease pathogenesis. Here, we used
mass spectrometry to quantify the relative abundance changes of phosphorylation sites due to
endogenous α-synuclein aggregation in a mouse model of progressive α-synuclein aggregation.
This resulted in the quantification of 2,763 and 2,112 phosphosites in wildtype (WT) and αsynuclein-null mice (Snca -/-), respectively. 126 and 65 phosphosites were significantly altered in
WT and Snca -/- mice, respectively. The amino acid distribution of the phosphosites did not
significantly deviate between the significant phosphosites and the total quantified phosphosites.
Endosome transport, membrane organization and vesicle-mediated transport were enriched
among the significantly altered phosphoproteins in WT, suggesting that various cellular signaling
processes respond to α-synuclein aggregation. Further interrogation of the phosphorylation
signaling changes that drives these processes would shed light on α-synuclein aggregationmediated neurotoxicity.

4.2 Introduction
α-Synuclein is a 140 amino acid protein that has roles in synaptic plasticity and neurotransmitter
release1. Progressive accumulation of α-synuclein aggregates underlies several
neurodegenerative diseases, including Parkinson’s disease (PD), collectively referred to as
synucleinopathies. PD is the second most common neurodegenerative disease in the United
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States and is characterized by dopaminergic degeneration and α-synuclein-positive intracellular
inclusions known as Lewy Bodies (LBs)2–4. Multiplications5–7 and point mutations8–12 in the gene
encoding α-synuclein, SNCA, cause PD. Additionally, purified wildtype and PD-linked mutant
forms of α-synuclein rapidly fibrillize in vitro13–16. Collectively, these data implicate α-synuclein
aggregation as a contributing factor in PD and related diseases.
Phosphorylation of α-synuclein deposited into LBs is increased at Ser-129 compared with soluble
α-synuclein17,18. LBs derived from other synucleinopathies, including multiple system atrophy
and dementia with Lewy Bodies, also contain abundant α-synuclein phosphorylated at Ser12917,18. The biochemical consequences of this phosphorylation on aggregation, membrane
binding, and neurotoxicity are unclear19. Studies expressing Ser-129A to prevent
phosphorylation or Ser-129D to mimic phosphorylation in rodent models and drosophila have
yielded conflicting results as to whether phosphorylation is neurotoxic or neuroprotective20–24.
Using cell free systems, most studies have found that phosphorylation of Ser-129 inhibits
fibrillization25,26, though some have found that it accelerates aggregation18.
This finding that α-synuclein phosphorylation is altered upon aggregation inspired our work. We
postulated that α-synuclein aggregation induces global perturbations in cellular signaling that
may contribute to neurodegeneration. To study these changes, we focused on phosphorylation
because of the documented increase in Ser-129 phosphorylation of α-synuclein upon
aggregation, and the importance of phosphorylation in regulating a multitude of critical cellular
activities. Using a recently developed mouse model of progressive aggregation of endogenous
α-synuclein27, we employed a quantitative phosphoproteomic approach to measure the relative
abundance changes of phosphosites due to α-synuclein aggregation.
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4.3 Experimental Procedures

Mouse Models Used in this Study: All handling of mice were performed according to the NIH
Guide for the Care and Use of Experimental Animals and approved by the University of
Pennsylvania Institutional Animal Care and Use Committee (IACUC). Wildtype (WT) C57BL6/C3H
mice were obtained from the Jackson Laboratories (Bar Harbor, ME). Snca -/- mice28 were
maintained on a C57BL6 background. 13C-Stable Isotope Labeling in Mammals (SILAM) mouse
brain tissue was purchased from Cambridge Isotope Laboratories, Inc (Female, L-Lysine 13C6,
97%).

Stereotaxic Injection of PFFs: Stereotaxic injection of pre-formed fibrils (PFFs) was performed as
previously described (see Chapter 3). Briefly, human WT α-synuclein fibrils were diluted in
sterile PBS and sonicated to produce PFFs. These PFFs were injected into the ventral striatum,
dorsal striatum and overlaying cortex of WT and Snca -/- mice. Mice were sacrificed 90 days post
injection by overdose with ketamine/xylazine.

Sample Preparation for LC-MS/MS: Briefly, the midbrain and striatum of the injected and noninjected sides were dissected and kept separate throughout the workflow. Two midbrain and
striatum regions of the injected side were combined to generate one biological sample for the
phosphoproteomic analysis. The same approach was employed for the non-injected side. Three
biological samples for WT and Snca -/- for each injected and non-injected side were analyzed
through the phosphoproteomic workflow. Sample preparation was done as previously described
in Carr et al.29, and in Chapter 3. After peptide separation by high-pH reverse phase
chromatography, 95% of peptides were combined in a concatenated pattern into 12 fractions
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for phosphoproteomic analysis. Lyophilized phosphopeptides fractions were resuspended in
50% acetonitrile/0.1% trifluoroacetic acid (TFA) and then diluted 1:1 with 100%
acetonitrile/0.1% TFA. These samples were then enriched for phosphorylation by incubation
with 10 µl with immobilized metal affinity chromatography (IMAC) for 30 min. Enriched IMAC
beads were the loaded onto C18 silica-packed stage tips, washed twice with 50 µl of 80%
acetonitrile/0.1% TFA and 100 µl of 1% formic acid. Phosphopeptides were then eluted from
IMAC beads with 3 washes of 70 µl 500 mM dibasic sodium phosphate, pH 7.0, (Sigma, S9763)
and 2 washes of 100 µl of 1% formic acid. Elution from stage tips was then performed with 60µl
of 50% acetonitrile/0.1% formic acid. Washes were performed on a tabletop centrifuge at a
maximum speed of 3,500 g.

LC-MS/MS and MS Database Searching and Data Processing: LC-MS/MS and MS Database
Searching using MaxQuant (1.5.1.2) was performed as described in Chapter 3.

Statistical Analysis: SILAC ratios were calculated as described in Chapter 3. Briefly, The
Heavy/Light (H/L) ratio in the non-injected side was divided by the H/L ratio in the injected side
to compute the injected/non-injected ratio of ratios. A phosphosite was considered quantified
in WT if this ratio of ratios was computed in in all 3 biological replicates; it was considered
quantified in Snca -/- if this ratio of ratios was computed in all 3 biological replicates. This
resulted in the quantification of 2,763 phosphosites (from 1,445 phosphoproteins) in WT and
2,112 phosphosites (from 1,110 phosphoproteins) in Snca -/-. A paired Student’s T-Test was
then used to calculate the significance of the differential expression for the phosphosites
quantified in WT and Snca -/-. p-Values < 0.05 were considered significant. This yielded 136
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phosphosites (from 124 phosphoproteins) in WT and 75 phosphosites (from 69
phosphoproteins) in Snca -/- that were significant. Next, we eliminated phosphoproteins that
overlapped between WT and Snca -/-, since we could not attribute the significant change to αsynuclein aggregation versus the PFF injection. There were 9 phosphoproteins that overlapped
in WT and Snca -/-. Eliminating these resulted in a final significant list of 126 phosphosites (from
115 phosphoproteins) in WT and 65 phosphosites (from 60 phosphoproteins) in Snca -/-.

Heatmap Generation: Heatmaps were created using pHeatmap in Rstudio. Clustering distances
were calculated by row and column with either Euclidean or Manhattan metrics, n- dimensional
real vector space with fixed Cartesian coordinate system, and clustered by either ward.D2 or
average linkage methodology, UPGMA.

Gene Ontology Enrichment Analysis: DAVID Bioinformatics Resources 6.7 was used for
enrichment analysis. For WT, the 1,445 quantified phosphoproteins in WT were used as
background. The 115 significantly changed phosphoproteins were used as a list and the
enrichment of Biological Processes was examined. Similarly for Snca -/-, the 1,110 quantified
phosphoproteins were used as background and the 60 significant phosphoproteins were used as
a list. Those biological processes with p-values < 0.05 were considered significant, and foldchanges were determined using the DAVID software.
4.4 Results
Quantitative Phosphoproteomics in PFF Mouse Model
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With the goal of quantifying changes in phosphorylation signaling in the brain due to α-synuclein
aggregation, we decided to use a modified version of a recently developed mouse model27. In
this model, α-synuclein pre-formed fibrils (PFFs) are intrastriatally injected into the right
hemisphere of a wildtype (WT) mouse brain. This induces a cascade of progressive α-synuclein
aggregation in synaptically connected regions, concomitant with dopaminergic degeneration in
the injected side only, and motor symptoms. Importantly, injection of PFFs into α-synuclein null
mice (Snca -/-) does not result in this phenotype. This model has been replicated in mouse30,31
and rats32, and recapitulates the cardinal features of Parkinson’s disease. We modified this
model to accelerate pathology by injecting triple the load of PFFs. 90 days post injection (dpi),
we documented a 19% loss of tyrosine hydroxylase positive neurons and increased α-synuclein
aggregation in the injected side of WT mice (see Chapter 3).
To measure the relative abundance changes of phosphorylation due to α-synuclein aggregation,
we employed a recently described quantitative mass spectrometry (MS) based methodology29.
This method utilized 13C-Stable Isotope Labeling in Mammals (SILAM)33,34 as an internal standard
to quantify phosphosite changes. First, we extracted the midbrain and striatum from the
injected and non-injected sides of the mouse that was sacrificed 90 dpi. The tissue from the
injected and non-injected sides was kept separate for the entire workflow (Figure 4.1). We
combined tissue from two mice for each biological replicate in order to have enough sample for
the phosphoproteomic analysis. The injected and non-injected sample from the PFF injected
mouse was then independently mixed with the SILAM tissues in a 1:1 ratio, followed by
homogenization, enzymatic peptide digestion, and separation by high-pH reverse phase liquid
chromatography (RPLC). These peptides were then enriched for phosphopeptides with
immobilized metal affinity chromatography (IMAC) followed by LC-MS/MS.
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To quantify phosphosites, a ratio of ratios approach was taken whereby the SILAM/Non-Injected
ratio was divided by the SILAM/Injected ratio to generate the Injected/Non-Injected ratio. This
allows us to compare the relative abundance change of a given phosphosite in the injected side
compared with the non-injected side. We performed three biological replicates for WT and
three for Snca -/-. We used Snca -/- to account for phosphosite changes induced by the injection
of PFFs. Our analysis resulted in the quantification of 2,763 phosphosites (from 1,445
phosphoproteins) in WT (Supplementary Table 11) and 2,112 phosphosites (from 1,110
phosphoproteins) in Snca -/- (Figure 4.2A, Supplementary Table 12). The distribution of the log2
transformed ratio of ratios for WT Snca -/- shows a unimodal distribution centered on log2=0
(Figures 4.2B and C).

Identification of Significantly Altered Phosphosites

To identify phosphosites whose relative abundance signififcantlty changed, several filtering
steps were applied. First, a paired Student’s T-Test was applied to each quantified phosphosite
in WT and Snca -/-. p-Values < 0.05 were considered significant, resulting in 136 (from 124
phosphoproteins) and 75 phosphosites (from 69 phosphoproteins) in WT and Snca -/-,
respectively. Then, phosphosites found in both WT and Snca -/- were excluded since the change
could be attributed to the injection of PFFs and not α-synuclein aggregation. After elimination of
the 9 phosphoproteins found in both groups, the final significant list consisted of 126
phosphosites (from 115 phosphoproteins) and 65 phosphosites (from 60 phosphoproteins) in
WT and Snca -/-, respectively (breakdown depicted in Supplementary Figure 4.1; Supplementary
Table 13). Volcano plots depicting the significant phosphosites in WT and Snca -/- depict the
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average differential expression versus significance (Figures 4.3A and B). Heatmaps generated
show that phosphosites that either significantly increase or decrease cluster together across
biological replicates, demonstrating the consistency in the relative abundance changes across
replicates (Figures 4.3C and D).

Exploration of Biological Processes and Pathways that are Altered in Response to α-Synuclein
Aggregation

Next, we interrogated the significantly altered phosphosites in order to elucidate changes in
signaling events in response to α-synuclein aggregation. First, the distribution of phosphorylated
amino acids in the significantly altered phosphosites was compared with the total quantified
phosphosites (Figure 4.4A). Serine phosphorylation comprised 85% - 93% of the total
phosphorylation, followed by threonine with 8% - 14% and tyrosine with 0% - 2%. Overall, no
significant deviations were detected, suggesting that significant changes did not preferentially
occur on a particular amino acid. Next, the enrichment of biological processes among the
significant phosphoproteins in WT and Snca -/- were determined (Figure 4.4B). Among WT
phosphoproteins, endosome transport, mitosis, membrane organization and neurological
systems were significantly enriched 2 – 7 fold. This is consistent with disruptions in cellular
signaling and the cell cycle. Among the significant Snca -/- phosphoproteins, only protein kinaserelated processes were enriched, suggesting that kinases respond to the injection of PFFs.
Finally, a global view of perturbed pathways in WT was determined (Figure 4.4C). This revealed
that vesicle-mediated transport and the immune system respond in WT, suggesting that cellular
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communication and defense systems are altered in response to endogenous α-synuclein
aggregation in the brain.

4.5 Discussion
The precise mechanisms by which dysfunction in cellular signaling pathways contributes to
neurodegeneration in PD and other synucleinopathies remains incompletely understood.
Initially, proteostasis mechanisms aimed at maintaining proper protein homeostasis, including
the ubiquitin/proteasome system, autophagy, and the unfolded protein response, are likely
perturbed due to α-synuclein aggregation. Later, cell-death pathways, including p53, JNK
signaling, cell-cycle reactivation, become involved35. Intervening with these later pathways could
provide a therapeutic strategy to mitigate the neurotoxicity associated with α-synuclein
aggregation in human disease
Our work aimed to shed light on changes in phosphorylation signaling induced by endogenous
α-synuclein aggregation in the brain. Given the documented changes in phosphorylation of
proteins implicated in PD, α-synuclein18 and the 14-3-3 proteins36, we reasoned that global
phosphorylation may be perturbed. We documented that 126 phosphosites were significantly
changed due to α-synuclein aggregation. These phosphoproteins were involved in various
aspects of cellular signaling, including endosome transport, vesicle-mediated transport and
neurological systems. Further investigation of these pathways may reveal phosphorylationmediated signaling events that contribution to dopaminergic degeneration in PD.
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Figure 4.1 Overview of Phosphoproteomic Workflow
The midbrain and striatum from the injected side of two mice are collected and combined. The
same is done from the non-injected side. These samples are then independently mixed and
homogenized in a 1:1 ratio with SILAM brain tissue. The mixture is then digested with trypsin
and LysC, followed by high-PH RPLC. 95% of the resulting peptides are then combined into 12
fractions in a concatenated pattern. IMAC enrichment is then used to enrich for
phosphorylated peptides. Following LC-MS/MS, the relative abundance changes of the
phosphopeptides are determined using a ratio of ratios calculation. Three biological
replicates in both WT and Snca -/- injected mice were completed.
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Figure 4.2 Phosphosites Quantified in WT and Snca -/(A) A phosphosite is considered quantified if the relative abundance change has been
determined in all three replicates. Using this criterion, 2,763 phosphosites (from 1,445
phosphoproteins) and 2,112 phosphosites (from 1,110 phosphoproteins) were quantified in WT
and Snca -/-, respectively.
Density plots of the log2 transformed ratio of ratios of (B) WT and (C) Snca -/-.
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Figure 4.3 Significantly Changed Phosphosites
Volcano plots showing average differential expression verses significance for (A) WT and (D)
Snca -/-. Red dots represent those phosphosites that have a p-value of < 0.05.
Heatmaps of unidirected clustering of the phosphosites that significantly changed in (C) WT and
(D) Snca -/- shows that the relative abundance changes are clustering by columns (injected
versus non-injected).
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Figure 4.4 Properties, Biological Processes and Pathways of Significantly Altered
Phosphoproteins
(A) Amino acid distribution of phosphosites quantified in WT, Snca -/-, including all and
significant phosphosites.
(B) Enriched biological processes of the significantly altered phosphoproteins in WT and Snca -/-.
In each set, the background was all the phosphoproteins quantified in that respective genotype.
(C) Global pathways that are enriched for significantly altered phosphosites in WT.
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Figure 4.1 Breakdown of Significantly Changed Phosphosites
All 2,763 phosphosites quantified in WT were used to identify the 116 phosphosites that
significantly changed.
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CHAPTER 5
Conclusions
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5.1 Summary and Conclusions
Neurodegenerative diseases present a significant challenge for healthcare systems, patients
afflicted by these diseases, and scientists attempting to understand their underlying
mechanisms and develop disease-modifying therapies. As populations continue to age, the
burden of these diseases is expected to worsen. The number of people afflicted with dementia
is expected to rise from over 46 million people today to over 130 million people by 20181. The
total cost associated with treatment and care is expected to rise from $818 billion today to over
$1 trillion in 20181. The development of effective disease-modifying therapies to treat these
diseases, especially Alzheimer’s disease (AD) and Parkinson’s disease (PD), is urgently needed.
AD is the most common neurodegenerative disease and the most common cause of dementia,
accounting for 60%-80% of cases2. In the United States, it is the sixth leading cause of death and
afflicts approximately 5.4 million people. This is expected to rise to 13.8 million people by 2050.
Age is the greatest risk factor, with one in nine people over the age of 65 diagnosed. Of the top
10 causes of death in the United States, only AD cannot be prevented or delayed3. Early
symptoms include difficulty remembering recent conversations, and apathy and depression.
Later symptoms include confusion, disorientation, poor judgment and eventually impaired
ability to walk, speak and eat.
PD afflicts 7-10 million people worldwide, including approximately 1 million people in the United
States4. The lifetime risk of developing PD is 1.5%5. Like AD, the greatest risk factor is age, with
the median onset age of 60 and 4 percent of cases being diagnosed before the age of 504. Men
are 50% more likely to develop PD than women6. Early symptoms of PD include subtle motor
deficiencies, including changes in writing, impairments in dexterity, and dragging one foot while
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walking7. As the disease progresses, symptoms include bradykinesia, resting tremor, rigidity and
slurred speech.
Underlying the pathology of both AD and PD, as well as other neurodegenerative diseases
including Amyotrophic Lateral Sclerosis and Huntington’s disease (HD), is protein aggregation8–
10

. Though many of the proteins that misfold in these diseases have been identified, the

relationship between this misfolding and neurodegeneration is unclear. Filling this gap would
shed light on biological pathways and molecular targets that could be modified to mitigate cell
death and thus provide a therapeutics relief. In this study, we focused on the aggregation of αsynuclein, a 140 amino acid protein that has roles in synaptic plasticity11. Aggregation of αsynuclein is implicated in several diseases, collectively known as synucleinopathies. Prominent
among these are PD and dementia with Lewy Bodies (DLB).
In these studies we aimed to quantitatively investigate the effect of endogenous aggregation of
α-synuclein on the proteostasis network of the brain. The proteostasis network refers to the
diverse and integrated cellular machinery and pathways that function to maintain proper
protein homeostasis, including protein localization, expression, degradation, folding and binding
partners12. We focused on changes in both protein and phosphorylation levels to study how the
proteostasis network is perturbed due to α-synuclein aggregation in the brain.
To accomplish this, we utilized a recently developed mouse model of endogenous α-synuclein
that recapitulates several cardinal features of PD. Aggregation is induced in this model by
intrastriatal injection of pre-formed fibrils (PFFs) of α-synuclein into non-transgenic (WT) mice13.
This aggregation of endogenous α-synuclein is progressive, spreading from near the site of
injection to synaptically connected regions over a 180-day period. Concomitant with this
progressive aggregation is dopaminergic degeneration and the onset of a motor phenotype,
117

both cardinal features of PD. Importantly, aggregation (in the midbrain and striatum) and
dopaminergic degeneration is confined to the injected side only, allowing us to use the noninjected side as an internal control. Finally, injection of PFFs into α-synuclein-null mice (Snca -/-)
fails to induce this pathology, allowing us to use these mice to control for the effect of the
injection on protein and phosphorylation levels. We used a modified version of this model
whereby mice were triple-injected instead of single-injected in order to accelerate pathology.
Before analyzing these mice further, we validated that the expected differences between the
injected and non-injected sides, and between the WT and Snca -/- mice, were maintained. We
found that α-synuclein phosphorylated at Ser-129, a marker for pathology14,15, was confined to
the injected side of WT mice. Additionally, we quantified a 19% loss in dopaminergic neurons in
the injected side of WT mice compared with the non-injected side, versus no loss in the Snca -/mice. After confirming these findings, employed a quantitative mass spectrometry (MS)-based
approach to measure the relative abundance changes in protein and phosphorylation levels due
to α-synuclein aggregation.
Our work quantified the relative abundance changes of 5,290 proteins in WT and 3,335 proteins
in Snca -/- mice and 2,983 phosphorylation sites in WT and 2,112 phosphorylation sites in Snca /-. Comparing the quantified proteins in our work to proteins identified in the mouse brain in
MS-based studies in the literature16–19 revealed no major differences in terms of molecular
weight, biological function or cellular localizations. This adds confidence that the proteins
quantified in our study do not significantly differ from those found in other studies. Additionally,
there were significant declines in the relative abundance of proteins selectively expressed in
dopaminergic neurons in WT but not Snca -/- mice, including tyrosine hydroxylase (TH),
aromatic-L-amino-acid decarboxylase (Addc), synaptic vesicular amine transporter-2 (VMAT2),
118

and dopamine transporter (DAT). The declines in TH, Addc and VMAT2 were validated by
Western blot, adding further confidence in our model and approach. Collectively, these analyses
demonstrate the comprehensiveness and selectivity of our approach, and add confidence in our
findings.
Statistical analysis of the quantified proteins and phosphosites resulted in the identification of
311 proteins (152 that increased and 159 that decreased in the injected side) and 133
phosphosites (from 121 phosphoproteins) whose relative abundance significantly changed. Of
the proteins that significantly changed, we found that RNA transport and the immune response
were enriched among the proteins that increased in the injected side, and that vesicle-mediated
transport, ion transmembrane transport and microtubule organization was enriched in the
proteins that decreased. Among the phosphoproteins that significantly changed, vesiclemediated transport and membrane organization were enriched. For the phosphoproteins we did
not separate the phosphosites that increased and decreased since the direction of the change in
relative abundance is not necessarily indicative of the change in activity (i.e. and increase in
phosphorylation does not necessarily mean an increase in activity). These enrichment analyses
from the proteomics and phosphoproteomics suggest that cellular signaling is perturbed in
response to α-synuclein aggregation, consistent with the documented dopaminergic
degeneration in this model and data from other studies13,20–22.
Of the 311 proteins and 135 phosphosites that significantly changed, we decided to focus on
Lmp7 (also known as proteasome subunit beta 8, or psmb8) for three reasons. First, it had the
greatest increase of the 152 proteins that significantly increased (236%). Second, it is involved in
the immune response, a topic that has garnered increased attention as a potential mediator of
α-synuclein aggregation-mediated toxicity in PD23. And finally, it is a catalytic subunit of the
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immunoproteasome, which has been implicated in protein aggregation diseases including AD
and HD24–26, but not in synucleinopathies. We first validated the increase detected by
proteomics by Western blot. Then, using human DLB samples, we found that Lmp7 levels and
activity were elevated in disease compared with healthy controls. This is, to our knowledge, the
first reported association between the immunoproteasome and synucleinopathies.
Lmp7 is one of the three cardinal subunits of the immunoproteasome. Upon stimulation by
proinflammatory cytokines or oxidative stress, expression of the catalytic subunits of the
immunoproteasome, namely Lmp2, MECL-1 and Lmp7, is elevated27,28. These proteins then
replace the catalytic subunits of the constitutive proteasome, namely β1, β2 and β5, respectively.
The immunoproteasome, which has different cleavage site preferences and catalytic activity
than the constitutive proteasome, generates antigenic peptides that are recognized by MHC
class I molecules29–32. These MHC class I molecules then present these peptides on the cell
surface for detection and destruction by CD8+ T cells33.
Though the immunoproteasome has not been directly linked to synucleinopathies, a recent
study found a link between MHC-I and dopaminergic neurons34. This study documented the
expression of MHC-I in the substantia nigra of both control and PD samples leading to a
proposed model that links MHC-I and dopaminergic degeneration. In this model, IFNγ induced
by the aggregation α-synuclein and the oxidative stress caused by cytosolic dopamine results in
the expression of MHC-I. This MHC-I is then loaded with antigenic peptides and exposed on the
cell surface for destruction by cytotoxic T cells (CTLs). Though the endogenous source of these
peptides was not considered, our work may provide the link.
The oxidative stress and IFNγ results in the increased expression of the immunoproteasome, as
we document in our studies. The immunoproteasome then interacts with and degrades α120

synuclein fibrils more efficiently than the constitutive proteasome. This is consistent with the
documented preference of the immunoproteasome to degrade basic proteins35. Furthermore, in
our studies using cell free systems, we demonstrate that degradation of α-synuclein fibrils
occurs more rapidly by the immunoproteasome than the constitutive proteasome. Furthermore,
the products of this degradation reaction are unable to accelerate the aggregation of soluble αsynuclein, a feature of bona fide protein aggregates9. The resulting α-synuclein peptides are
then loaded onto the MHC-I molecules for presentation to CTLs. Thus, dopaminergic neuron
degeneration in synucleinopathies may be enhanced by accelerated degradation of α-synuclein
by the immunoproteasome, leading to MHC-1 presentation on the cell surface, and recognition
by CTLs.
Alternatively, the degradation of α-synuclein fibrils by the immunoproteasome could be
neuroprotective. Though there is debate as to whether the aggregation of α-synuclein causes
cell death via a toxic gain-of-function or a toxic loss-of-function36, the finding that α-synucleinnull mice are viable and do not have shortened lifespan supports a toxic gain-of-function37,38.
Not surprisingly, many therapeutic strategies have attempted to remove α-synuclein aggregates
as a protective mechanism39. These include immunization against α-synuclein40,41, small
molecule inhibition of aggregation42,43, and the exogenous introduction of protein
disaggregases44. This last approach is particularly troublesome given the difficulty in introducing
these proteins intracellularly and the cofactors that are needed for these large protein
complexes to function. The immunoproteasome may provide a novel, endogenous therapeutic
target that can be modulated to mitigate α-synuclein-mediated neurodegeneration.
Augmentation of the immunoproteasome could accelerate α-synuclein degradation and thus
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retard neuron death. Additionally, engineering of the immunoproteasome may increase the
activity and selectivity for α-synuclein aggregates.
Determination of the role of the immunoproteasome in enhancing or mitigating
synucleinopathies is critical for the ultimate goal of therapeutic development. A key tool that
could be used to test this is the immunoproteasome-null mouse. These mice lack all three
catalytic subunit of the immunoproteasome and exhibit the expected defects in presenting
several classes of MHC-I epitopes45. Injection of PFFs into these mice followed by monitoring of
motor symptoms, dopaminergic degeneration, and α-synuclein aggregation would clarify the
role of the immunoproteasome. We expect decreased α-synuclein-positive aggregates in the
immunoproteasome-null injected mice. While enhanced dopaminergic degeneration and motor
symptoms would suggest a neuroprotective role for the immunoproteasome, decreased
degeneration and motors symptoms would be evidence for a neurotoxic role.
Ultimately, our work contributes three major new findings. First, we further characterized an
important mouse model of α-synuclein aggregation that will assist future researchers using this
model. Second, we provide a rich source of the relative abundance changes of proteins and
phosphosites in the brain in response to the endogenous aggregation of α-synuclein. This could
provide a valuable resource for investigators studying how proteostasis pathways respond to αsynuclein aggregation specifically, or protein aggregation broadly. Finally, we document, for the
first time, an increase in the levels and activity of the immunoproteasome in a human
synucleinopathy, and explore its activity against α-synuclein fibrils compared with the
constitutive proteasome. We believe the immunoproteasome is a putative therapeutic target
for treating synucleinopathies like PD and DLB, and merits further attention.

122

References
1.
2.

3.
4.
5.
6.
7.
8.
9.
10.

11.
12.
13.
14.
15.

16.

17.
18.

19.
20.

Prince, M. et al. World Alzheimer Report 2015. Alzheimer’s Dis. Int. 1 – 87 (2015).
Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D, Waters C, Jimison
P, Shepherd E, Sevush S, Graff-Radford N, Newland D, Todd M, Miller B, Gold M, Heilman
K, Doty L, Goodman I, Robinson B, Pearl G, Dickson D, D. R. Relative frequencies of
Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal
sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord 16, 203–212
(2002).
The Alzheimer’s Association. http://www.alz.org/facts/
Parkinson’s Disease Foundation. http://www.pdf.org/en/parkinson_statistics
Bower JH, Maraganore DM, McDonnell SDK, R. W. Incidence and distribution of
parkinsonism in Olmsted County, Minnesota. Neurology 52, 1214–1220 (1999).
Twelves D, Perkins KS, C. C. Systematic review of incidence studies of Parkinson’s disease.
Mov. Disord 18, 19–31 (2003).
Lees, A. J., Hardy, J. & Revesz, T. Parkinson’s disease. Lancet 373, 2055–2066 (2009).
Aguzzi, A. & Connor, T. O. Protein aggregation diseases: pathogenicity and therapeutic
perspectives. Nat. Rev. Drug Discov. 9, 237 – 248 (2010).
Jucker, M. & Walker, L. C. Self-propagation of pathogenic protein aggregates in
neurodegenerative diseases. Nature 501, 45–51 (2013).
Skovronsky, D. M., Lee, V. M. & Trojanowski, J. Q. Neurodegenerative Diseases: New
Concepts of Pathogenesis and Their Therapeutic Implications. Annu. Rev. Pathol. 1, 151 –
170 (2006).
Mor, D. E., Ugras, S. E., Daniels, M. J. & Ischiropoulos, H. Neurobiology of disease
dynamic structural flexibility of α-synuclein. Neurobiol. Dis. 88, 66–74 (2016).
Balch, W. E., Morimoto, R. I., Dillin, A. & Kelly, J. W. Adapting Proteostasis for Disease
Intervention. Science 319, 916 – 919 (2008).
Luk, K. C. et al. Pathological α-synuclein transmission initiates Parkinson-like
neurodegeneration in nontransgenic mice. Science 338, 949–53 (2012).
Fujiwara, H. et al. Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell
Biol. 4, 160–4 (2002).
Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological
modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem.
281, 29739–52 (2006).
Price, J. C., Guan, S., Burlingame, A., Prusiner, S. B. & Ghaemmaghami, S. Analysis of
proteome dynamics in the mouse brain. Proc. Natl. Acad. Sci. U. S. A. 107, 14508 –14513
(2010).
Sharma, K. et al. Cell type – and brain region – resolved mouse brain proteome. Nat.
Neurosci. 18, 1819 – 1831 (2015).
Walther, D. M. & Mann, M. Accurate Quantification of More Than 4000 Mouse Tissue
Proteins Reveals Minimal Proteome Changes During Aging. Mol. Cell. Proteomics 1–7
(2011).
Wang, H. et al. Characterization of the Mouse Brain Proteome Using Global Proteomic
Analysis Complemented with Cysteinyl-Peptide Enrichment. J. Proteome Res. 361–369
(2006).
Osterberg, V. R. et al. Progressive Aggregation of Alpha-Synuclein and Selective
123

21.

22.
23.
24.
25.
26.
27.
28.

29.
30.

31.

32.
33.

34.
35.
36.
37.
38.
39.

Degeneration of Lewy Inclusion-Bearing Neurons in a Mouse Model of Parkinsonism. Cell
Rep. 10, 1252–1260 (2015).
Paumier, K. L. et al. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into
rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol.
Dis. 82, 185–199 (2015).
Sacino, A. N. et al. Brain Injection of a-Synuclein Induces Multiple Proteinopathies,
Gliosis, and a Neuronal Injury Marker. Neurobiol. Dis. 34, 12368–12378 (2014).
Tufekci, K. U., Meuwissen, R., Genc, S. & Genc, K. Inflammation in Parkinson’s Disease.
Adv. Protein Chem. Struct. Biol. 88, 69–132 (2012).
Aso, E. et al. Amyloid Generation and Dysfunctional Immunoproteasome Activation with
Disease Progression in Animal Model of Familial Alzheimer’s Disease. Brain Pathol. 22,
636–653 (2012).
Orre, M. et al. Reactive glia show increased immunoproteasome activity in Alzheimer’s
disease. Brain 136, 1415–1431 (2013).
Dıaz-Hernandez, M. et al. Neuronal Induction of the Immunoproteasome in Huntington’s
Disease. J. Neurosci. 23, 11653–11661 (2003).
Ferrington, D. A. & Gregerson, D. S. Immunoproteasomes: Structure, Function, and
Antigen Presentation. Prog. Mol. Biol. Transl. Sci. 109, 75–112 (2012).
Heink, S., Ludwig, D., Kloetzel, P. & Kru, E. IFN-y-induced immune adaptation of the
proteasome system is an accelerated and transient response. Proc. Natl. Acad. Sci. U. S.
A. 102, 9241–9246 (2005).
Marques, J., Palanimurugan, R., Matias, A. C., Ramos, P. C. & Ju, R. Catalytic Mechanism
and Assembly of the Proteasome. Chem. Rev. 109, 1509–1536 (2009).
Chapiro, J. et al. Destructive Cleavage of Antigenic Peptides Either by the
Immunoproteasome or by the Standard Proteasome Results in Differential Antigen
Presentation. J. Immunol. 176, 1053–1061 (2006).
Cardozo, C. & Kohanski, R. A. Altered Properties of the Branched Chain Amino Acidpreferring Activity Contribute to Increased Cleavages after Branched Chain Residues by
the ‘Immunoproteasome’. J. Biol. Chem. 273, 16764–16770 (1998).
Lei, B. et al. Molecular Basis of the Selectivity of the Immunoproteasome Catalytic
Subunit LMP2-Specific Inhibitor Revealed by Molecular Modeling and Dynamics
Simulations. J. Phys. Chem. 12333–12339 (2010).
Dalet, A., Stroobant, V. & Vigneron, N. Differences in the production of spliced antigenic
peptides by the standard proteasome and the immunoproteasome. Eur. J. Immunol. 41,
39–46 (2011).
Cebrian, C. et al. MHC-I expression renders catecholaminergic neurons susceptible to Tcell-mediated degeneration. Nat. Commun. 5, 3633 (2014).
Raule, M., Cerruti, F. & Cascio, P. Enhanced rate of degradation of basic proteins by 26S
immunoproteasomes. BBA - Mol. Cell Res. 1843, 1942–1947 (2014).
Winklhofer, K. F. & Haass, C. The two faces of protein misfolding: gain- and loss-offunction in neurodegenerative diseases. EMBO J. 27, 336–349 (2008).
Abeliovich, A. et al. Mice lacking alpha-synuclein display functional deficits in the
nigrostriatal dopamine system. Neuron 25, 239–52 (2000).
Cabin, D. E. et al. Synaptic Vesicle Depletion Correlates with Attenuated Synaptic aSynuclein. J. Neurosci. 22, 8797–8807 (2002).
Rohn, T. Targeting alpha-synuclein for the treatment of Parkinson’s disease. CNS Neurol
124

40.

41.

42.
43.
44.
45.

Disord Drug Targets 11, 174–179 (2012).
Mandler, M. et al. Active immunization against alpha-synuclein ameliorates the
degenerative pathology and prevents demyelination in a model of multiple system
atrophy. Mol. Neurodegener. 1–15 (2015).
Valera, E. & Masliah, E. Pharmacology & Therapeutics Immunotherapy for
nNeurodegenerative Diseases: Focus on α-Synucleinopathies. Pharmacol. Ther. 138, 311–
322 (2013).
Caruana, M. et al. Inhibition and disaggregation of a-synuclein oligomers by natural
polyphenolic compounds. FEBS Lett. 585, 1113–1120 (2011).
H, C., VL, A.-B., NM, K. & JM, M. Intracellular screening of a peptide library to derive a
potent peptide inhibitor of α-synuclein aggregation. J. Biol. Chem. 290, 7426 – 7435
(2015).
Doyle, S. M., Genest, O. & Wickner, S. Protein rescue from aggregates by powerful
molecular chaperone machines. Nat. Rev. Mol. Cell Biol. 14, 617–629 (2013).
Kincaid, E. Z. et al. Mice completely lacking immunoproteasomes show major changes in
antigen presentation. Nat. Immunol. 13, 129–135 (2012).

125

